{
  "doc_id": "lung_SE",
  "created_date": "2024",
  "country": "SE",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": ". . . . .. . . ... . .. . . ... . .. . . ... . . . .. . . ... . . . .. . ... . . c c , a a . . .. . . o o .register register ...measures measures ... objectives. objectives... Quality indicators ... group group ...2. 2... and treatment... ... collaboration collaboration 2024-on on pre- __ __ MEDTERM4__; chapters. chapters.",
      "start_page": 1,
      "end_page": 13
    },
    {
      "heading": "healthcare healthcare course",
      "text": "from from RCC's website.",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "Legal Legal aid",
      "text": "care care provider'Act Act (2017:30). Act Act (2014:821) treatments treatments (3 Chapter 1–Patient Patient Act). care. care.",
      "start_page": 13,
      "end_page": 14
    },
    {
      "heading": "Evidence Evidence grading",
      "text": "and and Welfare'guidelines. guidelines.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Box/summary",
      "text": "• Sweden Sweden 2018–54, 54,8% were women. • 10 10 – women. women.• years. years. • combined. combined. • about about 28% (men 24%, women 31%). • average. average.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "and and forecast",
      "text": "Register Register [1], women women (54.8 % of cases). x x 10–cancer cancer [2]. reported reported [3]. 28 28 % in Sweden (24 % in women). cases cases (5, 5,292) cases cases (8, 8,598) diagnosis diagnosis [1]. the the patient'gender gender (see above), rate rate < 5% 8. 8.3%.",
      "start_page": 15,
      "end_page": 17
    },
    {
      "heading": "over over time",
      "text": "decreased decreased (Figure 2.2). 1. 1.2%, years years -2.0%. is is +1.5%, years years +0.7 %. men. men.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Sweden Sweden 1980–2021",
      "text": "cancer cancer (age-standardised age-standardised incidence) women women (Figure 2.3).is is -0.1% and and +2.2% 1. 1.1% about about 11% increase. increase.",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "International International perspective",
      "text": "Union Union (EU) was around 44% 15. 15.4%, EU EU (27 countries) x x 10–women women [4]. Greece Greece (Figure 2.4). Denmark Denmark (Figure 2.4). 25. 25.4% (diagnosis 2013-2019) [5].",
      "start_page": 19,
      "end_page": 20
    },
    {
      "heading": "Executive summary",
      "text": "• least least 80% disease. disease. • around around 10% Sweden. Sweden. • smokers. smokers. • cancer. cancer. • lung lung cancer; cancers. cancers.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Tobacco Tobacco smoking",
      "text": "explains explains 80-90% Sweden. Sweden. 90% about about 10% Ratio Ratio (OR) 1 1 [7, 8]. Ratios Ratios (ORs) ex-smokers ex-smokers (95% CI) 9 9 (19,2–29,0). often often 10–least least 10–after after 10–diseases diseases (4 4 Tobaksprevention). about about 25% non-smoking. non-smoking.",
      "start_page": 21,
      "end_page": 22
    },
    {
      "heading": "Occupational Occupational exposure",
      "text": "than than 10% population population (Swedish Swedish conditions), population population (Swedish Swedish circumstances) seen. seen.",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "3.3 Radon",
      "text": "lung lung cancer; exposure. exposure.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "3.4 Inheritance",
      "text": "cases cases [9]. 2. 2.5–6.8% age age [10]. cancer cancer [11]. recommended. recommended.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "in in never-smokers",
      "text": "world world [12]. patients patients (in in total) register register (2002 and onwards), unchanged unchanged (about 15% and and 10% for men) period period [13]. patients patients [13]. cancer. cancer.",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Recommendations",
      "text": "• cancer. cancer. • treatment. treatment. • The individual patient'contact. contact. • chemotherapy chemotherapy [24]. link link [25].",
      "start_page": 26,
      "end_page": 27
    },
    {
      "heading": "tobacco tobacco use",
      "text": "stop stop smoking? using using tobacco? of of \"Do you smoke?\" used used tobacco?",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "quit quit smoking",
      "text": "the the patient'do do it; the the future? menu menu [26]. treatment treatment (behavioral tips). foundation foundation – with with (smoke-free smoke-free life). and and encouraging! stop. stop. Stop-own own unit's efforts.",
      "start_page": 27,
      "end_page": 28
    },
    {
      "heading": "quit quit smoking",
      "text": "may may be: motivation motivation / ability to succeed? with with something? x x weeks? return return visit? first first step? knowledge knowledge [26]. cancer, cancer, he/outcome outcome [25]. incentive. incentive.",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "care care unit",
      "text": "week. week.",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "Pharmacological Pharmacological treatment",
      "text": "top top [27]. studies studies [28, 29]. effective effective [30]. support. support.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "medicinal medicinal products",
      "text": "the the patient'spray spray [31]. prop. prop.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "2 2 Varenicline",
      "text": "about about 1/sacred sacred date",
      "start_page": 29,
      "end_page": 30
    },
    {
      "heading": "3 3 Cytisin",
      "text": "days days (see schedule below) Agency Agency (LMV). use use Cytisin: - the the medicine; recent recent stroke; pregnancy; nicotine. nicotine.",
      "start_page": 30,
      "end_page": 31
    },
    {
      "heading": "4 4 Bupropion",
      "text": "combined combined (though rarely necessary). effect effect [32]. seizures. seizures.",
      "start_page": 31,
      "end_page": 32
    },
    {
      "heading": "drug drug metabolism",
      "text": "stops. stops.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "tobacco tobacco calls",
      "text": "use. use.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "4.6 Conclusions",
      "text": "the the doctor'doctor doctor – associations. associations.",
      "start_page": 32,
      "end_page": 33
    },
    {
      "heading": "smoking smoking cessation",
      "text": "Sweden Sweden – call 020–tobacco tobacco information: and Stop-the the clinic/care unit'efforts. efforts.",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Recommendations",
      "text": "• studies studies (NLST and NELSON) DT. DT. • population population (Swedish Swedish one) known. known. • investigated. investigated. • screening. screening.",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "5.1 Introduction",
      "text": "population. population. • stages. stages. • disease. disease. • risk risk population; • phases. phases.",
      "start_page": 34,
      "end_page": 35
    },
    {
      "heading": "of of screening",
      "text": "Trial Trial [35] (see below) 96 96 %, cancer. cancer. 11% diagnostics. diagnostics. • examinations. examinations. • lung lung cancer; X-ray X-ray and/alone. alone.",
      "start_page": 35,
      "end_page": 36
    },
    {
      "heading": "CT CT scan",
      "text": "Trial Trial (NLST) [35] project project – Trial Trial – NLSLT NLSLT [41]. age, age, race/of of 83% to to 71% 3. 3.4% to 4 %. 1000 1000 person- 76 76 (0.61–0.94; p = 0.01) 67 67 (0.38-1.14). to to 24% 2019 2019 [44] arm arm (6 6 years) shown shown 39% mortality mortality (HR 0.61), 95% CI 0.395) and 58% Work Work (STB) and and 6% and and 11% planning planning group'Database Database (REG SO) measures. measures.",
      "start_page": 36,
      "end_page": 39
    },
    {
      "heading": "tomography tomography (DT) and and are",
      "text": "patients. patients.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "• stability stability over",
      "text": "considered. considered.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "• size size of",
      "text": "profile. profile.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "• Solid changes 6–after after 6–",
      "text": "individual. individual.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "• changes changes > given given to:",
      "text": "tumour investigation.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "• changes changes (semi-solid, ground-glass) < 6 mm",
      "text": "up. up.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "• changes changes ≥ with with DT",
      "text": "after 3–6 months (semi-solida) and 6–12 months (ground ice cream), of of 1–years. years.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "• after after 3-6",
      "text": "years. years.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "tomography tomography (DT) of",
      "text": "problem. problem.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "genes, genes,",
      "text": "previous previous edition: • mm. mm. • preferences. preferences. • document. document. • 2017 2017 [45]. website website [46]. below. below.",
      "start_page": 40,
      "end_page": 41
    },
    {
      "heading": "6.2 Applicability",
      "text": "or or older; lung lung cancer; infections. infections.",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "General General recommendations",
      "text": "DT-sections DT-sections (≤ 1.5 mm) changes changes ≤ follow-ups. follow-ups.",
      "start_page": 41,
      "end_page": 42
    },
    {
      "heading": "Nodual Nodual Changes",
      "text": "changes changes < is is < 1%, individuals individuals (see below), change change 6–after after 6–localisation localisation (see above), after after 18–months. months.",
      "start_page": 42,
      "end_page": 43
    },
    {
      "heading": "Risks Risks Follow-up",
      "text": "< follow-up follow-up (< 100 mm3) moons. moons. 6–following following 6–after after (100–Risk Risk 18–24 Mons. mm3) after after 6–after after 18–after after 3–Risk Risk 1–4 Moons.",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "Nodule Nodule Changes",
      "text": "DH ≥ neoplasms neoplasms ≥ neoplasm neoplasm < following following events: the the estimate: island island (than than men) risk risk factors: target (",
      "start_page": 43,
      "end_page": 45
    },
    {
      "heading": "Executive summary",
      "text": "• symptoms symptoms (of of breath), X-ray. X-ray. • disease. disease. • smokers. smokers. • syndrome. syndrome. • smokers. smokers.",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "1 1 Cough",
      "text": "long-drawn long-drawn cold",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "2 2 Haemoptysis",
      "text": "in in < 1% of of 3-10% care care [47-49]. haemopties haemopties [50]. 2. 2.5-9% to to 35% mucus. mucus.",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "3 3 Dyspnoea",
      "text": "disease disease (COPD), cancer cancer (37–58%) trachea. trachea.",
      "start_page": 47,
      "end_page": 48
    },
    {
      "heading": "Torax Torax pain",
      "text": "tumour tumour (sulcus superior tumour) palate. palate.",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "General symptoms",
      "text": "loss loss (anorexia), appetite appetite (cakexia), of of care",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "and and Kakexi",
      "text": "factor-alpha factor-alpha (TNF-α), 6 6 (IL-1, IL-6) and interferon-gamma (IFN-gama). planned. planned.",
      "start_page": 48,
      "end_page": 49
    },
    {
      "heading": "2 2 Fatigue",
      "text": "than than 50% only only 10% other other disease- fatigue. fatigue.",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "3 3 Fever",
      "text": "infection. infection.",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "4 4 Depression",
      "text": "about about 20%. regional regional dispersal",
      "start_page": 49,
      "end_page": 50
    },
    {
      "heading": "disorders disorders (suspension)",
      "text": "surgery. surgery. Horner'symptoms. symptoms.",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "Cardiovascular Cardiovascular impact",
      "text": "wall wall (caput medusae), approximately approximately 75% causing causing 40-50% cancers. cancers.",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "mediastinal mediastinal distribution",
      "text": "cause. cause.",
      "start_page": 51,
      "end_page": 52
    },
    {
      "heading": "1 1 CNS",
      "text": "the the patient'weight weight (e.g. ).",
      "start_page": 52,
      "end_page": 53
    },
    {
      "heading": "2 2 Skeleton",
      "text": "approximately approximately 25% vertebrae vertebrae (70%), pelvis (40%) and femur (25%). about about 20% blood blood changes: marrow. marrow.",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "3 3 Liver",
      "text": "approximately approximately 35% finding finding (approximately 70%). gas gas findings",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "4 4 Adrenals",
      "text": "be be 25-40% hypofunction hypofunction (Addison) abdomen abdomen (investigation investigation chapter).",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "Paramalignant Paramalignant syndromes",
      "text": "production production (and and cytokines). approximately approximately 10% below. below.",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "1 1 SIADH",
      "text": "in in 60-70% on on 50% and and 50% plasma plasma (< 270 mOsm/kg) and and nausea/S-Na S-Na < 130 mmol/hyponatremia hyponatremia (S-Na < 115 mmol/L) hypoenteremia. hypoenteremia.",
      "start_page": 54,
      "end_page": 55
    },
    {
      "heading": "ACTH ACTH syndrome",
      "text": "in in 30-50% than than 5%. production. production.",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "3 3 Hypercalcaemia",
      "text": "Approximately Approximately 15% peptide peptide (PTH-rP), anorexia, anorexia, nausea/ days. days.",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "4 4 Gynaecomastia",
      "text": "choriogonadotropin choriogonadotropin (HCG) seen. seen.",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "neurological neurological symptoms",
      "text": "cancer cancer (body body weight).",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "Thromboembolic disease",
      "text": "DIC DIC (disseminated intravascular coagulation) inhibitors inhibitors (and and edoxaban) metastases metastases [51].",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "Hypertrophic Hypertrophic Osteoartropathy",
      "text": "phalanges phalanges (clubbing) ankles. ankles.",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "healthcare healthcare course",
      "text": "symptoms symptoms (of of breath) as as hemotpty'Investigation Investigation – propagation. propagation.",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "in in Science",
      "text": "lung. lung. & Both Both in: AT AT (Eds). Cancer Cancer (4th Edition): Cancer Cancer (IASLC). Philadelphia: Lippincott Williams & Wilkins 2010:327-351.",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "Recommendations",
      "text": "• KVAST. KVAST. • samples samples (biopsy/cytology), origin. origin.",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "• classification, classification, with:",
      "text": "the the tumour'1 1 Pathology'being being new/synchron or relapse/very very difficult; internal internal and/conference conference (MDK). Re-if if 1) sample sample (cytology/biobiobiob/restect) tester tester (cythology/b biobiops/reservate), a a k/a a . toxicity toxicity (ROSE) analyses analyses (unhistochemical unhistochemical staining) of of ng/CytoRich. CytoRich.",
      "start_page": 58,
      "end_page": 61
    },
    {
      "heading": "2 2 Biopsy",
      "text": "buffered buffered 4% formaldehyde solution (equivalent to 10% formaldehyde). biopsies. biopsies.",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "3 3 Traveled",
      "text": "or or perfusion/for for biobanking/bio-banking bio-banking / on on biopsy/preferably preferably 10–system. system.",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "referral referral information",
      "text": "the the following: • Patient'number number • physician physician • infection infection (suspected suspected tuberculosis) • If frozen/so so telephone/searcher number • sampling sampling • fixation fixation • Preparation type (several several preparations) • Clinical assessment/prior prior PAD/cytology, rö/etc. etc. • on on assessment/question-answering question-answering (including if clinical/lungtum lungtum metastasis) assessment. assessment.",
      "start_page": 62,
      "end_page": 62
    },
    {
      "heading": "Tumour Tumour classification",
      "text": "chromocytosis chromocytosis (chapter acneumonous anthropocytosis) (acryptocytopenic acryptocytopenic anthrophytes) (e.g., abdominal abdominal anthromones) (pneumonic pneumonic anthracene) (nodule absolutous aphneumony) (abnormal abnormal abscessors). from from 202) the the WHO/chronococtone chronococtone (mcncdc) mcdp (mnccdncchcdchmn) meccnic (Mncnhcccndcmc) ccddccmdcnmcclcdmcdkmnmnncmndmn.mcmpncrmcs (Mcnbcn) ctccchncclccpnddmmngcmmcr) cfcctcnpcchcn accrccmin (in in mcnxmclmcpl/Cyptcphcpcnnppcpplcc (see above) ne ne ad) ent ent rad) alala alala ala",
      "start_page": 62,
      "end_page": 64
    },
    {
      "heading": "1 1 Adenocarcinoma",
      "text": "cancer-depleted cancer-depleted (e.g., neocytodrin-pneumonous neocytodrin-pneumonous neophytes) 1 1 % airspace airspace (STAS). adenocarcinoma adenocarcinoma (MIA) a a ≤ of of ≤ into into vascular/airspace airspace (STAS). resectate resectate (except ≥ 10 % intracytoplasmic intracytoplasmic mucine).",
      "start_page": 65,
      "end_page": 66
    },
    {
      "heading": "cell cell carcinoma",
      "text": "of of A's keratinisation (including beading), B'bridge, bridge, C') marker marker (CK5, CK5/6, p40, p63) focal focal (i.e. ≥ 10% incolored tumour cells). forms forms (neuroendocrine neuroendocrine cancer) positive positive TTF-1/A A (A A positive) CK5. CK5.",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "cell cell cancer",
      "text": "Focal Focal (< 10%) marker marker (CK5, CK5/or or p63) as as ≥ cancer cancer (NSCC) negative. negative.",
      "start_page": 67,
      "end_page": 67
    },
    {
      "heading": "cell cell cancer",
      "text": "each each other's cores (by definition > 2 2 mm2) of of ≥ 10% carcinoma carcinoma (by any proportion). staining staining (see further below).",
      "start_page": 67,
      "end_page": 67
    },
    {
      "heading": "neuroendocrine neuroendocrine cancer",
      "text": "differentiation differentiation (peripheral peripheral palissadation) marker marker (and and CD56). mitoses mitoses (by definition > 2 2 mm2) 4 4 (small cell cancer) cells cells and/chromatin chromatin (relatively relatively common) and/considered. considered.",
      "start_page": 67,
      "end_page": 68
    },
    {
      "heading": "6 6 Carcinoid",
      "text": "divide divide low/define define typical/parallel parallel sequencing/NGS (of of sequence) NGS NGS (RNA RNA level) recommended. recommended. Genrearrangement/nGS nGS (RNA RNA levels) cells cells (cytological cytological test). on on biopsy/infection infection (organ organ transplant). surrounding reactive changes), examined examined areas/proportion proportion (1) viable tumor, (2) necrosis and (3) stroma (and and fibrosis) in 10% interval (if if <5%) be be 100%. Viable tumour ≤10% is counted as",
      "start_page": 68,
      "end_page": 71
    },
    {
      "heading": "Recommendations",
      "text": "• symptoms symptoms (of of breath) generously. generously. • examination. examination. • procedures procedures (SVF) cancer cancer (VGM) the the following: topical. topical. • treatment. treatment. • the the patient'place. place. • yourself. yourself. • course course (SVF) care care (SVB)*. stages stages [54]. significantly significantly [55]. suspicion suspicion (VGM) met. met.",
      "start_page": 72,
      "end_page": 74
    },
    {
      "heading": "suspicion suspicion (are are present)",
      "text": "information information (9. 9.3). that that • procedure procedure • made made • investigation investigation • numbers. numbers.",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "be be told:",
      "text": "• suspicion suspicion • phase phase • website. website.",
      "start_page": 74,
      "end_page": 75
    },
    {
      "heading": "lung lung cancer",
      "text": "condition condition (performance status) metformin metformin (be be < be be made). performed. performed.",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "X-ray images",
      "text": "telephone telephone number",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "patients",
      "text": "the the patient'structural structural examination: For mediastinal staging: - Primarily: EBUS, EUS. Secondly: D D and/performed performed (before before D/E) performed. performed.",
      "start_page": 75,
      "end_page": 78
    },
    {
      "heading": "studies studies Action",
      "text": "processing processing decisions",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "9.2 Names",
      "text": "package package years: per per day/fatigue. fatigue.",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "Grade Functionality",
      "text": "strenuous strenuous activities; any any work; than than 50% limited limited self- care; 50 50 % 4 4 Can'any any self-treatment; completely bedridden",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "Clinical examination",
      "text": "recurrenspares recurrenspares (clinical clinical findings).",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "Blood Blood tests",
      "text": "rate rate (GFR) (GFR GFR (estimated GFR, eGFR_) used used (Regime Regime Library*) antigen antigen (CEA) enolas enolas (NSE) only only % of a A) DNA DNA (ctDNA) in plasma (SCID biopsy) it. it.",
      "start_page": 79,
      "end_page": 80
    },
    {
      "heading": "Developmental Developmental diagnostics",
      "text": "the the patient'test test (e.g., an ecclesiastical test). metastasis metastasis [57]. media media (and skeletal algorithm) carcinoma carcinoma (_MEDTERM0___). __MEDTERM0_, __MEDTERM0_, 10-15% diagnosis diagnosis [58]. cases, cases, DT/limited. limited.",
      "start_page": 80,
      "end_page": 82
    },
    {
      "heading": "9.6 Bronchoscopy",
      "text": "lavage lavage (BAL) sampling. sampling.",
      "start_page": 82,
      "end_page": 83
    },
    {
      "heading": "Mediastinal Mediastinal Scenario",
      "text": "are are present: • position position • nodes nodes – cN1 – glands glands – tumor > localisation localisation (FDG FDG uptake) required required at: • tumor tumor ≤ N0. N0.",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "1 1 EBUS/EUS",
      "text": "CBTC CBTC (or or PET-DT) breakthrough breakthrough (central tumour compression), over over 20% esophagus esophagus (e. g. erythrocytes) priority priority (the the recommendation). register register (Thor) about about 20% guidelines. guidelines. (a) tumor tumor > patients. patients.",
      "start_page": 84,
      "end_page": 87
    },
    {
      "heading": "pulmonary pulmonary puncture",
      "text": "approximately approximately 35% the the tumor'size. size.",
      "start_page": 87,
      "end_page": 88
    },
    {
      "heading": "Sputum Sputum Cytology",
      "text": "physiotherapist. physiotherapist.",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "Recommendation",
      "text": "below. below.",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "Pleural Pleural Diagnosis",
      "text": "about about 50%. pleura. pleura.",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "Intra-abdominal Intra-abdominal metastases",
      "text": "EUS. EUS.",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "marrow marrow examination",
      "text": "not not 100%.",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Superficial Superficial metastases",
      "text": "decision. decision.",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Explorative Explorative toracotomy",
      "text": "dissection dissection (Surgical Surgical treatment). surgery. surgery.",
      "start_page": 89,
      "end_page": 90
    },
    {
      "heading": "Summary recommendations",
      "text": "- population. population. • obesity obesity (BMI > 30), co-morbidity. co-morbidity. • treatment. treatment. • recommended. recommended. • surgery. surgery. - performed. performed.",
      "start_page": 90,
      "end_page": 90
    },
    {
      "heading": "cancer cancer surgery",
      "text": "2013. 2013.",
      "start_page": 91,
      "end_page": 91
    },
    {
      "heading": "Clinical Clinical evaluation",
      "text": "obesity obesity (BMI > 30), treated. treated.",
      "start_page": 91,
      "end_page": 92
    },
    {
      "heading": "Work Work tests",
      "text": "individuals individuals > this this [62] of of his/capacity capacity (DLCO) capacity capacity (DO). receive receive > 80% pulmatology. pulmatology.",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "4 4 Ergospirometrics",
      "text": "DLCO DLCO < 60 %, uptake uptake (VO max) of > 20 ml/kg/values values < 10 ml/ kg/surgery surgery [65-67]. 10-20 10-20 ml/Kg/ventilation ventilation (VE/VCO slope) guidance guidance [65]. efficiency efficiency (VE / VCO2 –slope) of of 10–20 ml/km/min [68]. surgery. surgery.",
      "start_page": 92,
      "end_page": 93
    },
    {
      "heading": "Stairway Stairway test",
      "text": "DLCO DLCO 30-60% [69] (see algorithms). VO VO -ergospirometry ergospirometry (r = 0.7). 86 86 % 15 15 ml/kg/min. [70]. the the walk/co-mortalities co-mortalities (e.",
      "start_page": 93,
      "end_page": 93
    },
    {
      "heading": "6 6 Pulmectomy",
      "text": "pulmmectomy pulmmectomy [71]. capacity capacity (DLCO) FEV FEV % pulmpectomy, pulmpectomy, ventilation/FEV FEV . pulmphectomy. pulmphectomy.",
      "start_page": 93,
      "end_page": 94
    },
    {
      "heading": "lung lung function",
      "text": "or or bilobectomy: ppoFEV = x x (1 - y / Z) 19 19 (lung lung [the the lower] lung lung [the the bottom]). in in pulmectomy: ppofEV = FEVx FEVx (1 - resected resected lung). bronchodication bronchodication (post-BD). lung. lung.",
      "start_page": 94,
      "end_page": 94
    },
    {
      "heading": "Statutory Statutory classification",
      "text": "Tchronophyllum (Tc)-cct. cct.) Sweden. Sweden. (Tb) distribution distribution (T), metastases metastases (N) metastasis metastasis (M). classification classification (cTNM) validation validation (see below) 7th 7th edition: of of trachea'levels levels (IVA and IVB). version version (7th edition), disease disease (lithed disease, LD) disease disease (extensive disease, ED). disease disease (extrangary disease, ED). anthrombocyte anthrombocyte (N N – classification classification (UICC/edition edition 2016) diameter diameter > 3 ≤ 5 cm (T2a > 1 ≤ 4 cm; T2b > 4 ≤ 5cm) characteristics characteristics (head head bronchitis; diameter diameter > 5 cm;",
      "start_page": 94,
      "end_page": 96
    },
    {
      "heading": "M – Remote metastases",
      "text": "metastatics. metastatics. (pleuraexsupate pleuraexsupate uni- pericardial pericardial fluid; outside outside torax; outside outside torrax). cancer cancer (UCC/IASCL version 8) T2 T2 T3",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "TUMMER SIZE",
      "text": "T1a T1a ≤T2a T2a >3 ≤4 cm >5 ≤T1b T1b >1 ≤b b >4 ≤c c >2 ≤multiplicity multiplicity Metastasis/same same lobe",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "ATELEKTAS",
      "text": "or or lung",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "CENTRAL PLANT",
      "text": "main main bronchi",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "PERIFER PLANT",
      "text": "parietalis parietalis and/T4 T4 > m m Metastases/IM IM > 3 ≤ b b > 5 ≤ metas metas > contr contr pleura/the the lung",
      "start_page": 97,
      "end_page": 99
    },
    {
      "heading": "Conference",
      "text": "years years have",
      "start_page": 100,
      "end_page": 100
    },
    {
      "heading": "levels. levels.",
      "text": "and and Welfare'made. made.",
      "start_page": 100,
      "end_page": 100
    },
    {
      "heading": "and and high",
      "text": "cancer. cancer.",
      "start_page": 100,
      "end_page": 100
    },
    {
      "heading": "the the country",
      "text": "clinical clinical physiology/involved. involved.",
      "start_page": 100,
      "end_page": 100
    },
    {
      "heading": "recommendations recommendations for:",
      "text": "a a \"coke book\" a a \"regime library\" treatment treatment – projects projects – cancer. cancer.",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "tumour tumour stage",
      "text": "programmes. programmes.",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "treatment treatment of",
      "text": "surgery surgery (PS) cancer cancer (_MEDTERM9_) I-II I-II (local disease) performance performance (PS), anatomy anatomy lob-, bilob- methamphetamine methamphetamine (VATS) status (PS). pressure pressure (≥ 50% in tumour cells), of of cyt$section section (see also dan).",
      "start_page": 101,
      "end_page": 103
    },
    {
      "heading": "III III (loco-regionally advanced disease)",
      "text": "• treatment. treatment. • III. III. • I-II. I-II. • considered considered (see below).",
      "start_page": 103,
      "end_page": 104
    },
    {
      "heading": "General General principles",
      "text": "• decisions. decisions. • products products (and and chemotherapy) survival. survival. • __ __ MEDTERM0__-, BRAF-, ERBB2, KRAS- and and _MEDTERMS2___; tumor. tumor. • control. control. • disease. disease. • rosiness. rosiness.",
      "start_page": 104,
      "end_page": 104
    },
    {
      "heading": "Targeted Targeted therapy",
      "text": "plasma plasma (ctDNA) REGIO REGIO • EGFRTKI EGFRTKI • analysis. analysis. PK_MEDENT_PREUT_QT_M/CW/CYT_XTHR_TEC_THRP_TOP_TMP_TEP_TCP_TTP_TPT_TED_TOT_TRE_TOD_TEST_TEM_TTE_Test_Tem_Tome_tem_tat_tome_Treat_Town_Telephone_Tema_Tate_Tac_Tat=or or TB_TRT_T_TAT_Tak_T",
      "start_page": 104,
      "end_page": 106
    },
    {
      "heading": "endobronchial endobronchial therapy",
      "text": "• cough. cough. • Gy. Gy. • tissue. tissue. • radiotherapy radiotherapy (brachytherapy) above.",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "I-III I-III (restricted disease)",
      "text": "following following regimens: for for relapse/treatment treatment (after after completion) considered. considered.",
      "start_page": 106,
      "end_page": 107
    },
    {
      "heading": "• of of non-",
      "text": "IIIA IIIA – M0. M0. • IIIa IIIa – T1/T4 T4 N0/surgery. surgery. • surgery. surgery.",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "• purpose purpose and",
      "text": "• anatomical anatomical lob-, bilob- surgery surgery (WATS) today today – studies studies – spread. spread. • tumours tumours (<with with > 50% solid component) verified verified pre- or perioperatively. • explosion explosion (sampling or dissection) removed. removed.",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "disorders. disorders.",
      "text": "In In T1/position position (not subcarinal) neoadjuvant neoadjuvant and/metastases metastases (and and radiotherapy) assessment assessment (see below).",
      "start_page": 108,
      "end_page": 109
    },
    {
      "heading": "development development areas",
      "text": "excluded. excluded. It'by by 24% (2. 2.2%) perioperatives perioperatives (and and adjuvant) II-IIIA II-IIIA [82]. therapy. therapy.",
      "start_page": 109,
      "end_page": 110
    },
    {
      "heading": "Functional Functional investigation",
      "text": "function function (and and ergospirometrics), working ability (work test), cardiac function (coronary coronary angiography) condition condition (enl. enl. WHO). Investigation. Investigation.",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "Pre-operational Pre-operational sequencing",
      "text": "with with EBUS/Investigation. Investigation.",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "for for surgery",
      "text": "complications complications [83]. missing missing [84]. prehabitation. prehabitation.",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "or or VAT?",
      "text": "VATS VATS [85-87]. VATS VATS [85-87). least least 50% of of eri- 2. 2.5% in Sweden [91]. study study (Lung) term term \"breeding\" that that \"bombroatone\" or \"benchnointing\" means a ‘bombombone' Nations Nations (of of America) Macedonia. Macedonia.",
      "start_page": 111,
      "end_page": 114
    },
    {
      "heading": "1 1 — node node map",
      "text": "resection resection [96]. stages stages [97]. survival survival [98]. etc. etc. [99]. dissection dissection (HR 0.78). reported. reported.",
      "start_page": 115,
      "end_page": 116
    },
    {
      "heading": "Post-operative Post-operative care",
      "text": "time time (see below), of of long- and/after after 1–prophylax. prophylax.",
      "start_page": 116,
      "end_page": 117
    },
    {
      "heading": "12.7 Complications",
      "text": "following following effects: itself itself (the fistula) diet diet (medium triglycerides) and/leak leak (to to find) stage. stage.",
      "start_page": 117,
      "end_page": 118
    },
    {
      "heading": "Adjuvant Adjuvant treatment",
      "text": "with with PD-L1>50% therapy therapy (1. 1.1). cancer cancer (2. 2.6).",
      "start_page": 118,
      "end_page": 118
    },
    {
      "heading": "Post-operative Post-operative follow-up",
      "text": "treatment. treatment.",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "12.10 Forecast",
      "text": "Today Today (January 2021) average average 63% Sweden Sweden [91]. around around 80% barely barely 40% IIIA. IIIA.",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "13.1 Introduction",
      "text": "approximately approximately 20% about about 50% for for 10% IV IV [100]. therapy therapy (stereotactic radiotherapy) use. use.",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "adverse adverse reaction",
      "text": "considered. considered.",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "1 1 Pneumonitis",
      "text": "10 10 mg/exceed exceed 3–FEV FEV < 1.0 L/detonates detonates 3– treatment. treatment.",
      "start_page": 120,
      "end_page": 121
    },
    {
      "heading": "2 2 Esophagitis",
      "text": "Gy Gy [104], dose dose [105], below below 17% [103]. rare rare [106].",
      "start_page": 121,
      "end_page": 122
    },
    {
      "heading": "3 3 Cardiotoxicity",
      "text": "cancerca cancerca [107]. low low (V5) treatment treatment [cm3 cm3 < 03 03 cm3< Lungs Lungs (minus minus GTV) V20 < 35% V5 < 65% D medium < Dicides Dicides < Agents Agents < V60 V60 < 17% cm3 cm3 ≤ V25 V25 < 10 % D Agent < below below 50% drug. drug.",
      "start_page": 122,
      "end_page": 123
    },
    {
      "heading": "Recommendation",
      "text": "• 3. 3. • SBRT SBRT (Stereotic BodyTherapy), control control (88-90% at five years) studies studies [109-115]. control control (or or bronchia). study study (HILUS) Gy Gy [116]. but but for",
      "start_page": 123,
      "end_page": 124
    },
    {
      "heading": "Recommendation",
      "text": "• of of PET/brain. brain. • is is recommended: − Gy Gy − therapy therapy − with with _$expression expression ≥ 1% months. months.",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "planning planning data",
      "text": "athelectase athelectase [122] diagnostic diagnostic PET/DT study [123]. DT. DT.",
      "start_page": 125,
      "end_page": 126
    },
    {
      "heading": "Treatment Treatment technique",
      "text": "technology technology (VMAT) DIBH DIBH (breath breath hold), protons protons (RTOG 1308), 2017. 2017.",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "Treatment Treatment volumes",
      "text": "volume volume (GTV). the the tumor'Volume Volume (ITV) volume volume (CTV), ITV ITV (if if 4D/been been performed), volume volume (PTV).",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "of of treatment",
      "text": "dose dose [125]. toxicity toxicity [126-128]. studies studies [129, 130]. 0617 0617 [108]. patients. patients.",
      "start_page": 126,
      "end_page": 127
    },
    {
      "heading": "5 5 Fractionation",
      "text": "fractions fractions (hyperfraction) treatment treatment (accelerating), Gy Gy [132]. treatment treatment [133], insufficient. insufficient.",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "Combination Combination chemotherapy",
      "text": "control control [134]. 2-4 2-4 [135] were were compared: therapy therapy (2 2 daily) induction. induction.",
      "start_page": 127,
      "end_page": 128
    },
    {
      "heading": "Concomitant Concomitant Radiochemotherapy",
      "text": "radiochematherapy radiochematherapy [138, 139]; radiokemotherapy radiokemotherapy (0. 0.74) 7 7 % 10 10 % oesophageal oesophageal [138]. noted. noted.",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "Cytostatic Cytostatic Choices",
      "text": "cancer cancer [140], therapy therapy (HR 0.87; CI 0.87–0.99), chemotherapy chemotherapy (HR0.88; 73-1. 73-1.06). reactions reactions [141]. carboplatin. carboplatin.",
      "start_page": 128,
      "end_page": 129
    },
    {
      "heading": "Subgroup Subgroup analyses",
      "text": "meta-analyses meta-analyses [137, 138, 140], meta-analysis meta-analysis [138], loss loss > 5%, aged aged > stages stages [145-147). state state (0-2 0-2 group). levels levels [145-147] radiotherapy. radiotherapy.",
      "start_page": 129,
      "end_page": 130
    },
    {
      "heading": "radiation radiation therapy",
      "text": "benefit benefit [149-154]. dose dose (54-60 Gy). paraortial paraortial (station station (st. st. 4), window window (p. p. 6) involved (ps.",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "stage stage IIIA/N2 NSCLC",
      "text": "chemotherapy chemotherapy [81] increases [160, 162]. surgery surgery [163]. Gy. Gy.",
      "start_page": 130,
      "end_page": 131
    },
    {
      "heading": "lung lung cancer",
      "text": "cancer cancer (_MEDTERM0__) limited limited (limited, LD) and widespread (extensive, ED) 5 5 % years years [165], 4 4 (ED) immunotherapy immunotherapy (cell cell pneumonia).",
      "start_page": 131,
      "end_page": 132
    },
    {
      "heading": "I-III I-III (Limited Disease, LD)",
      "text": "stage stage I-III: • afterwards. afterwards. • Gy. Gy. • CR. CR.",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "1 1 Timing",
      "text": "concomitant concomitant (same same time), sequential (by by radiotherapy) a a 5% chemotherapy chemotherapy [166].",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Radiation Radiation dose",
      "text": "levels levels [167-169]. years, years, 70% versus 46% (p=0.002) reactions reactions [170]. weeks weeks (RTOG 0538). recommended. recommended.",
      "start_page": 132,
      "end_page": 133
    },
    {
      "heading": "3 3 Fractionation",
      "text": "to to 10% fraction fraction [171]. oesophagitis oesophagitis > from from 11% to 27%. toxicity toxicity [172]. days days [173]. above. above.",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Treatment Treatment volume",
      "text": "2020 2020 [174].",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "5 5 Cytostatics",
      "text": "instead. instead.",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "irradiation irradiation (PCI)",
      "text": "I-III I-III > 50% 5. 5.4% treatment treatment [175]. patients patients (> 80 years) fractions fractions [176] PCI PCI [177, 178].",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "IV IV (widespread disease, ED)",
      "text": "to to chemotherapy: • months. months. • remission. remission.",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "toracal toracal radiotherapy",
      "text": "follow-up follow-up [179]. 9. 9.1% versus 3.7%. up up [180]. survival survival (primary endpoint), TRIPLEX. TRIPLEX.",
      "start_page": 134,
      "end_page": 135
    },
    {
      "heading": "irradiation irradiation (PCI)",
      "text": "A large (n=286) chemotherapy chemotherapy [181]. PCI PCI [182].",
      "start_page": 135,
      "end_page": 135
    },
    {
      "heading": "Recommendation",
      "text": "is is recommended: • Gy. Gy. • Gy. Gy.• recommended recommended that: • technique. technique. • 5. 5. • 1. 1. • shrinkage. shrinkage.",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "Primary Primary Tumour",
      "text": "Often, Often, patients' life life [183]. oesophageal oesophageal (approximately 15-20%). study study (612 patients) in in 3% of patients [184]. line. line.",
      "start_page": 136,
      "end_page": 137
    },
    {
      "heading": "RT RT (brachytherapy)",
      "text": "effect effect [185]. hospitals. hospitals.",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "Remote Remote Metastases",
      "text": "treatment treatment [188] effect. effect.",
      "start_page": 137,
      "end_page": 138
    },
    {
      "heading": "disease disease (OMD)",
      "text": "is is expected:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "__MEDTERM0_Situation __MEDTERM0_Situation I-III",
      "text": "treatment treatment (surgery or radiotherapy), here. here.",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "Recommendation:",
      "text": "with with _$expression expression (≥ 50% in tumour cells), initiated. initiated.",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "Adjuvant Adjuvant Treatment",
      "text": "2015 2015 [196], chemotherapy chemotherapy (p=0.04; trend analysis). Cisplatin + 2015 2015 [196], chemotherapy chemotherapy (P=0.04). survival survival (DFS) _MEDTERM0___ _MEDTERM0___ (17-0. 17-0.26); p < 0.0001). 2023 2023 [197], was was 90% vs. 44% data data (ALINA) trial trial (IMTERM67_) Impower010 Impower010 [202]. meta-analysis meta-analysis (included included studies) [204], period period 1990–survival survival (HR). 76. 76.1% vs. 63.4%, 63. 63.8% vs. 45.3% (63 63 - 0.91); p=0.005; 83. 83.2% vs. 75.4%; response response (pCR) was 24.0% vs. 2.2%. PD-L1 PD-L1 expression; months months [20] hereL1-pression hereL1-pression ≥1% weight weight (preoperative preoperative (neoadjuvant) post-operative post-operative (adjucant) study study (AEGEAN) Phase Phase IIIB), following following recommendation: expression expression 1% recommendation. recommendation.",
      "start_page": 140,
      "end_page": 146
    },
    {
      "heading": "medicinal medicinal products",
      "text": "and and recommendations: • chemotherapy. chemotherapy. • ranges. ranges. • used. used. • least least 1% therapy. therapy.",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "pathology pathology testing",
      "text": "several several modalities: __ __ MedTERM0__-, __MINTERM1__, _MEDTERMS2_, BRAF-, KRAS-, analyses. analyses.",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "Recommendation:",
      "text": "__ __ MEDTERM2__). • MedTERM-29__TKI MedTERM-29__TKI (__MEDERM3___. • with with __INTERM1__) PD-1 PD-1 (Programmed Death-1) or PD-L1 (Death Death Ligand-1).",
      "start_page": 147,
      "end_page": 148
    },
    {
      "heading": "1 1 EGFR",
      "text": "CENTRE_XTHRET__00_000_ml_x_ml/ml_ml._mlt_m_mlD_mlL_ml=ml_mm_ml-ml_jp_ml,_mt_ml%the the best-of of 37% MEDTERM34__ MEDTERM34__ + 2023 2023 [220] by by __MediaM34___+median median ___MM85_$with with __MIDEM34_+with with ___MEDTERm4_(70 70 [0.58–0.85]; p<0.001) as as __MediterraneanM34=prescription. prescription.",
      "start_page": 148,
      "end_page": 151
    },
    {
      "heading": "with with EGFR-TKI",
      "text": "combination combination __MEDTERM5_+ __mediaM24___-TKi __mediaM24___-TKi (Ex19del or L858R) line line [227] line line [228), to to __CONTERM2/generation generation _MEDTERMS24_$generation generation _ITERM3__Y_TQI",
      "start_page": 151,
      "end_page": 152
    },
    {
      "heading": "prior prior EGFR-TKI",
      "text": "common common (approximately 16%) [229]. __MEDTERM20_k_mutated __MEDTERM20_k_mutated (Ex19del or L858R) __INTERM9__ __INTERM9__ (see above) + __ __ CONTERM3__$ with with _MEDTERMS5_+months months with__MEDERTERM5-, with _ONMEDTERAM5_/MEDTERMAT_+MEDTERIM5_(MEDTERMP8_+ only only (4 4 [0.36-00.64] respectively] respective HR[better better treated__",
      "start_page": 152,
      "end_page": 153
    },
    {
      "heading": "4 4 ALK",
      "text": "x_xL__ch__s__f__en__g__ x_xL__ch__s__f__en__g__ ,__MM__y__p__d__t__r__b__e__c__tr__/__;ceritinib(__)treatment-provided treatment-provided treatment-study study (ALTA-1L) 62. 62.5% 5 5 % __MEDTERRM0__. __MEDTERRM0__.",
      "start_page": 154,
      "end_page": 155
    },
    {
      "heading": "prior prior ALK-TKI",
      "text": "with with __MEDTERM_30_/trial trial are:_MIT_00_mt_j_jp_jb_jc_jd_jn_jf_jw_jk_jx_jg_jv_jj_kl_jr_jrc_jzp_hp_chp_k_kt_kb_kp_y_jq_jsp_j.",
      "start_page": 155,
      "end_page": 156
    },
    {
      "heading": "6 6 ROS1",
      "text": "treatment. treatment.",
      "start_page": 157,
      "end_page": 157
    },
    {
      "heading": "7 7 BRAF",
      "text": "in in 1-2% V600E V600E (> 80%). with with _$MEDTERMM0__ (BRAF inhibitors) MEDTERM1_ MEDTERM1_ (MEK inhibitors) of of 66% treatment treatment (n = 57) [247], and 64% patients patients (n=36) [248). it. it.",
      "start_page": 157,
      "end_page": 157
    },
    {
      "heading": "genetic genetic variants",
      "text": "__ITTERM0__, __ITTERM0__, . and and _MEDTERMS4_/tumours tumours (see above), of of 32% [251, 252]. 6 6 mg/kg (e. g. pneumontitis). IMTER_473_EN_EN/EN_FR_ENX_ENQ_ENI_ENT_en_ENWY_EN",
      "start_page": 158,
      "end_page": 161
    },
    {
      "heading": "Recommendation:",
      "text": "• a a cytone-failure. failure. __MEDTERM1_01%. significant significant (76 76 [0.54-1.09)) [26]. study study (EMPOWER-Lung 1) products products (Impower150 Impower150 [272] paclitaxel paclitaxel (BCP), or or 3) BCP BCP (ABCP) population (see above) regimen regimen (CVTHR) 12 12 g/ dl (1.25 mmol/ l). e. e., tumour tumour and/condition. condition. • carboplatin carboplatin + paclitaxel/in in 20-30% from from 20% to 29%. response response (e. g., pneumonitis, and pneotherapy). 59___. 59___. _$__MediaM111__-mutations __MediaM111__-mutations (Targeted Targeted therapy).",
      "start_page": 161,
      "end_page": 169
    },
    {
      "heading": "2 2 Immunotherapy",
      "text": "10 10 % expression expression < 1%, or if PD- intolerance. intolerance.",
      "start_page": 169,
      "end_page": 171
    },
    {
      "heading": "3 3 Cytostatics",
      "text": "patients patients (see above). therapy therapy [294]. docetaxel docetaxel [295]. line line (see below), considered. considered.",
      "start_page": 171,
      "end_page": 172
    },
    {
      "heading": "Other Other preparations",
      "text": "agent. agent.",
      "start_page": 172,
      "end_page": 172
    },
    {
      "heading": "Recommendation:",
      "text": "• disease disease (stage stage I-III), platinum platinum + radiotherapy. radiotherapy. • radiation radiation (PCI). • disease disease (stage stage IV) with with platinum+ __ITTERM1__. __ITTERM1__. • platinum platinum + option. option. • considered. considered. •be be considered; • alternative. alternative.",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "1 1 General",
      "text": "cancer cancer [299, 300], poor poor (3–4), area. area.",
      "start_page": 173,
      "end_page": 174
    },
    {
      "heading": "I-III I-III treatment",
      "text": "small small [303-306]. disease disease (stage stage I-III), radiation radiation (PCI). chemotherapy. chemotherapy.",
      "start_page": 174,
      "end_page": 175
    },
    {
      "heading": "IV IV treatment",
      "text": "carboplatin carboplatin + Platinum Platinum + option option (see below). odication. odication.",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "1 1 Immunotherapy",
      "text": "=MITRE_CHR_QT_THR_TCR_TEC_Treat_Tem_Test_tem_tm_tome_tat_tak_tp_tc_twp_et_tun_tb_tof_tch_t of_tv_ts_t,_t=ttt_td_tn_t._t-tem/3. 3.",
      "start_page": 175,
      "end_page": 176
    },
    {
      "heading": "Relapsing Relapsing treatment",
      "text": "an an end-regimen regimen (e. g. pneumonitis). SCLC SCLC [315]. topotecan topotecan (respectively, respectively, p=0.01). was was 6%. in in relapse; relapse. relapse.",
      "start_page": 177,
      "end_page": 178
    },
    {
      "heading": "Executive summary",
      "text": "dies dies [316]. • curative. curative.",
      "start_page": 179,
      "end_page": 179
    },
    {
      "heading": "15.1 Dyspnoea",
      "text": "mechanism. mechanism. Dosage: mg mg sc/or or 4–6 times/shortness. shortness. Dosing: 10 10 mg/ condition. condition.",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "Oxygen Oxygen treatment",
      "text": "of of hypoxia: • acidosis • phenomena phenomena • radiotherapy radiotherapy • frenicuspares • airways airways • heart failure • pulmonary embolism • pericardial fluid • pneumothorax pneumothorax • liver liver • system system • syndrome syndrome • to to anxiety",
      "start_page": 180,
      "end_page": 181
    },
    {
      "heading": "Pleural Pleural fluid",
      "text": "situation, situation, patients' volumes volumes > difficulties. difficulties. X- fluid fluid (000 000 ml/week) performed. performed.",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "Pleuode Pleuode treatment",
      "text": "5 5 g/be be insuffler",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "Persistent Persistent catheters",
      "text": "pleurodes, pleurodes, eller",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "Pericardial Pericardial fluid",
      "text": "phenestration. phenestration.",
      "start_page": 182,
      "end_page": 182
    },
    {
      "heading": "15.5 Cough",
      "text": "In In life'saliva saliva and/glycopyrrone glycopyrrone (Robinul) IV. IV.",
      "start_page": 182,
      "end_page": 182
    },
    {
      "heading": "15.6 Haemoptysis",
      "text": "endobronchial endobronchial (brachytherapy). the the patient'dilation. dilation.",
      "start_page": 182,
      "end_page": 183
    },
    {
      "heading": "Stamping Stamping pairs",
      "text": "lathesis lathesis (be be withdrawn).",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "superior superior syndrome",
      "text": "stent. stent.",
      "start_page": 183,
      "end_page": 184
    },
    {
      "heading": "15.9 Hypercalcaemia",
      "text": "PTH-rP PTH-rP (PTH-related protein) disease. disease. Treatment: • cases cases (S-Ca > 4). • bisphosphonate. bisphosphonate. • bisphonates. bisphonates.",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "15.10 SIADH",
      "text": "hyponatremia hyponatremia (s-Na < 115) or or 3% FASS. FASS. • S-Na< 135 mmol/l • Osmolality < 275 mOsm/kg • U-osmolality > 100 mOSm/ kg • Clinical euvolaemia • U‐Na > 40 mmol/intake intake • function function • diuretic diuretic treatment",
      "start_page": 184,
      "end_page": 185
    },
    {
      "heading": "Brain Brain metastases",
      "text": "the the patient'action action (SRT) patients patients (up to 3-4).",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "Bone Bone metastases",
      "text": "risk risk and/70-80 70-80 % delay. delay.",
      "start_page": 185,
      "end_page": 186
    },
    {
      "heading": "Endobronchial therapy",
      "text": "the the patient'death death [318].",
      "start_page": 187,
      "end_page": 187
    },
    {
      "heading": "tumour tumour growth",
      "text": "the the patient'action action (5. 5.2). the the airways: • trachea trachea and/bronchials. bronchials. • perfusion. perfusion.",
      "start_page": 188,
      "end_page": 188
    },
    {
      "heading": "upcoming upcoming compression",
      "text": "trachea trachea and/bronchi. bronchi. • obstruction. obstruction. • obstruction obstruction – intervention. intervention. • stent stent (see below). • added. added.",
      "start_page": 189,
      "end_page": 191
    },
    {
      "heading": "16.4 Haemoptysis",
      "text": "radiotherapy. radiotherapy.",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "16.5 Fistles",
      "text": "empyem. empyem.",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "16.6 Brakytherapy",
      "text": "malignancy malignancy susspecta/ ablation ablation (RFA), therapy therapy (PDT), fra fra (see NCT03569111; NCT040057; information. information.",
      "start_page": 191,
      "end_page": 192
    },
    {
      "heading": "Recommendation",
      "text": "• nurse. nurse. • e. e.",
      "start_page": 193,
      "end_page": 193
    },
    {
      "heading": "must must update",
      "text": "• this. this. • smoking. smoking. • setting. setting.",
      "start_page": 193,
      "end_page": 193
    },
    {
      "heading": "Contact Contact nurse",
      "text": "the the patient'healthcare healthcare (SOU 2009:11–2010) Act Act (cancercentrum. cancercentrum.se/co-operation/patient-and-narstaende/oc oc 1).",
      "start_page": 193,
      "end_page": 193
    },
    {
      "heading": "care care plan",
      "text": "Future Future (SOU 2009:11) centre centre (Social Social Affairs: 2011).",
      "start_page": 194,
      "end_page": 194
    },
    {
      "heading": "Active Active handover",
      "text": "During the patient'should should be",
      "start_page": 194,
      "end_page": 194
    },
    {
      "heading": "Cancer Cancer Rehabilitation",
      "text": "The The patient'basis. basis.",
      "start_page": 194,
      "end_page": 195
    },
    {
      "heading": "to to them",
      "text": "Chapter Chapter 5§ them. them. Children'also also Socialstyrelsen's \"Children as relatives\" (family family members: die, die, 2013)",
      "start_page": 195,
      "end_page": 195
    },
    {
      "heading": "specialised specialised rehabilitation",
      "text": "recovery. recovery.",
      "start_page": 195,
      "end_page": 195
    },
    {
      "heading": "Recommendation",
      "text": "• competence. competence. • the the disease'condition. condition. • the the patient'and and patient' palliative palliative care: • activity activity and/patient patient ́well-being. well-being. • paralysis paralysis (central central injury) metastases. metastases. • aids. aids. • surgery. surgery. • therapist. therapist. • surgery. surgery.",
      "start_page": 196,
      "end_page": 196
    },
    {
      "heading": "Recommendations",
      "text": "health health (mental mental illness) your your patient'life. life.",
      "start_page": 197,
      "end_page": 197
    },
    {
      "heading": "Recommendations",
      "text": "• care. care. • model. model. • patient. patient. • life life [324]. professionals. professionals.",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "PLISSIT PLISSIT model",
      "text": "model model [325]. the the model'issued. issued.",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "2 2 Fertility",
      "text": "important. important.",
      "start_page": 198,
      "end_page": 199
    },
    {
      "heading": "and and self-care",
      "text": "and and Welfare'lifestyles lifestyles (living living habits). brochure brochure \"in in Cancer\" (Care Care Association).",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "8 8 Tobacco",
      "text": "00. 00.",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "9 9 Alcohol",
      "text": "48. 48.",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "Physical Physical activity",
      "text": "counts. counts.",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "Eating Eating habits",
      "text": "problems. problems.",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "alternative alternative medicine",
      "text": "website. website.",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "Solar Solar habits",
      "text": "shade. shade.",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "and and support",
      "text": "Association Association (see Appendix 1) find find up-decision. decision.",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "oncological oncological treatment",
      "text": "therapists therapists and/Programme. Programme.",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "2 2 Nausea",
      "text": "library. library.",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "and and cough",
      "text": "patient. patient.",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "Respiratory Respiratory distress",
      "text": "breath breath (dyspnoea) the the patient'care. care.",
      "start_page": 201,
      "end_page": 202
    },
    {
      "heading": "2 2 Cough",
      "text": "the the patient'Hosta. Hosta.",
      "start_page": 202,
      "end_page": 202
    },
    {
      "heading": "and and end-of-life care",
      "text": "the the patient'care. care.",
      "start_page": 202,
      "end_page": 202
    },
    {
      "heading": "for for disposal",
      "text": "of of patients' following following paragraphs: • both both symbolic/a a practical/context. context. • the the person/situation. situation. • patient. patient. • Patient'involvement. involvement. • The The patient'in in his/most most patients' are are now?",
      "start_page": 203,
      "end_page": 204
    },
    {
      "heading": "health health care",
      "text": "situations situations [328]. safe safe port",
      "start_page": 204,
      "end_page": 205
    },
    {
      "heading": "and and participation",
      "text": "a a patient'diagnosis diagnosis [331], care care (al, al, 2011) the the patient' autonomy autonomy [335]. patient patient ́their their vulnerability/saying saying \"no\" . the the question\" [335] doctor doctor [335]. expectations expectations [336]. a a patient'life life [334; the the doctor: • about about • the the patient' the the patient; • conclusion. conclusion.",
      "start_page": 205,
      "end_page": 206
    },
    {
      "heading": "mental mental maneuvers",
      "text": "cancer cancer [337]. losses losses [338] future future [339] ones ones [340]. life life [341]. usual usual [341]. patients patients by: • treatment. treatment. • anxiety. anxiety. • When the patient'usual. usual.",
      "start_page": 206,
      "end_page": 207
    },
    {
      "heading": "3 3 Related",
      "text": "a a child'a a patient'the the patients' the the patient' Act Act (5 Chapter 7§) support support (SFS 2017:31). how how parents/situation situation [344] the the parent'relatives relatives by: • psychologists psychologists • the the patient'behaviour behaviour • minors minors • more more questions",
      "start_page": 207,
      "end_page": 208
    },
    {
      "heading": "Psychosocial Psychosocial treatment",
      "text": "above above (18.2), the the patient'patient patient ́care. care.",
      "start_page": 208,
      "end_page": 208
    },
    {
      "heading": "Psychosocial Psychosocial interventions",
      "text": "needs needs [345]. the the patient'promote promote patients' and relatives' needs. needs. Patients' vulnerability vulnerability [348]. a a patient'also also called",
      "start_page": 209,
      "end_page": 211
    },
    {
      "heading": "Recommendation investigation:",
      "text": "• abdomen. abdomen. • receptor receptor PET/propagation. propagation.",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "• tumours tumours (higher Ki67%), consider also FDG-",
      "text": "PET. • Do bronchoscopy/assessment. assessment. • S-cortisol. S-cortisol.",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "Recommendation treatment:",
      "text": "• tumors. tumors. • radicality. radicality. • inoperable. inoperable. • carcinoid. carcinoid. • metastases. metastases.",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "System treatment:",
      "text": "• Somatostatin analogues (SSA) indices. indices. • growth. growth. • receptors. receptors. • Cytostatics: streptozotocin streptozotocin + disease. disease.",
      "start_page": 213,
      "end_page": 213
    },
    {
      "heading": "1 1 Introduction",
      "text": "proportion proportion (abdominal abdominal organs), tumours tumours (NET) trials. trials.",
      "start_page": 213,
      "end_page": 213
    },
    {
      "heading": "2 2 Existence",
      "text": "0. 0.6–10-5 10-5 [302, 351, 352]. approximately approximately 100–period period 2018–2. 2.7% cancer cancer (on on Registration). Approximately Approximately 2/women. women.",
      "start_page": 213,
      "end_page": 213
    },
    {
      "heading": "3 3 Etiology",
      "text": "48 48 % 5 5 % 17 17 % in adenocarcinoma (NLCR Report 2022). rates rates [353]. 1 1 (MEN 1), DIPNECH DIPNECH (see below), carcinosis. carcinosis.",
      "start_page": 214,
      "end_page": 214
    },
    {
      "heading": "4 4 Pathology",
      "text": "Carcinoid. Carcinoid.",
      "start_page": 214,
      "end_page": 214
    },
    {
      "heading": "and and Symptoms",
      "text": "and and .uncommon uncommon (functional tumours), and and Cushing'in in 1–3% valve. valve. • oedema. oedema.",
      "start_page": 214,
      "end_page": 215
    },
    {
      "heading": "6 6 Investigation",
      "text": "FDG FDG -PRRT PRRT (radiouclide radiouclide therapy), carcinoids carcinoids (80 80 %) receptors. receptors.",
      "start_page": 215,
      "end_page": 216
    },
    {
      "heading": "1 1 Surgery",
      "text": "general general (Surgical Surgical treatment). needed needed [356].",
      "start_page": 216,
      "end_page": 216
    },
    {
      "heading": "Locoregional Locoregional Treatment",
      "text": "carcinoma carcinoma [358]. conference conference [351, 358]. cancer. cancer.",
      "start_page": 216,
      "end_page": 216
    },
    {
      "heading": "System System therapy",
      "text": "observed observed (4. 4.4) of of < 20 %, pressure pressure (HR) 48 48 (bronchial bronchial carcinoid) survival survival (p p = 0.037) better better (39% agents agents (e. g. pneumocoxib). form. form.",
      "start_page": 217,
      "end_page": 219
    },
    {
      "heading": "and and forecasting",
      "text": "steroids steroids [382] considered considered [383].",
      "start_page": 219,
      "end_page": 220
    },
    {
      "heading": "Recommendations",
      "text": "• year. year. • metastas. metastas. • mesothelioma. mesothelioma. • appropriate. appropriate. • line. line. • experience. experience.",
      "start_page": 221,
      "end_page": 221
    },
    {
      "heading": "1 1 Introduction",
      "text": "prognosis. prognosis.",
      "start_page": 221,
      "end_page": 221
    },
    {
      "heading": "2 2 Epidemiology",
      "text": "Sweden. Sweden. 80% older. older.",
      "start_page": 221,
      "end_page": 221
    },
    {
      "heading": "3 3 Etiology",
      "text": "studies studies [350], 80-90 % exposure. exposure.",
      "start_page": 222,
      "end_page": 222
    },
    {
      "heading": "Natural Natural Progress",
      "text": "pain pain (computer computer tomograms). patient patient becomes",
      "start_page": 222,
      "end_page": 223
    },
    {
      "heading": "5 5 Symptoms",
      "text": "lung lung (torax torax half) half. half.",
      "start_page": 223,
      "end_page": 223
    },
    {
      "heading": "Laboratory Laboratory findings",
      "text": "patients patients (with with relapse). markers markers (or or osteopontine) mesothelioma. mesothelioma.",
      "start_page": 223,
      "end_page": 224
    },
    {
      "heading": "7 7 Diagnosis",
      "text": "cholelithonia cholelithonia (e. g. pneumothropoic) symptoms symptoms (pain pain ), mesothelioma mesothelioma (a a crucible) fluid. fluid. PET/DT (Positron-Emissions-Tomography/Datortomography) biopsy. biopsy.",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "8 8 Pathology",
      "text": "common common (10-15%) value value (see above).",
      "start_page": 224,
      "end_page": 225
    },
    {
      "heading": "Statutory Statutory classification",
      "text": "mesoteliomas mesoteliomas (1. 1.2) IMIG IMIG (Interest Interest Group). only only N0–surgeons surgeons [387] (2. 2.2).",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "10 10 Forecast",
      "text": "diagnosis diagnosis [388]. stage. stage.",
      "start_page": 226,
      "end_page": 226
    },
    {
      "heading": "1 1 Surgery",
      "text": "treatment treatment [389]. pulmectomin pulmectomin - contemplated contemplated - recommended recommended - Surgery Surgery (ThoR) - mesothelioma. mesothelioma.",
      "start_page": 226,
      "end_page": 227
    },
    {
      "heading": "2 2 Radiotherapy",
      "text": "puncture puncture channels/doubtful doubtful [390] metastases. metastases.",
      "start_page": 227,
      "end_page": 227
    },
    {
      "heading": "3 3 Immunotherapy",
      "text": "1 1 % to 3 % weight weight (CHR) 3 3 % to 10 % patients. patients.",
      "start_page": 227,
      "end_page": 227
    },
    {
      "heading": "4 4 Cytostatics",
      "text": "to to 20% survival survival [393]. arm arm (HR 0.77; P = 0.020). 41. 41.3% and 16.7%, respectively (p < 0.0001) 500 500 mg/75 75 mg/ 18. 18.6% and 25% months. months.",
      "start_page": 228,
      "end_page": 228
    },
    {
      "heading": "5 5 Progression",
      "text": "10 10 % failure failure (ppemtrexed ppemtrexed + possibly bevacizumab_) __ITTERM1_ __ITTERM1_ (2 2 weeks) patients patients (third-line, third-line, n=332, 2:1 randomisation). group group (69, 69, p=0.009). study study [365]. population. population. - study study (n=154, 2:1 randomised), o o (60 60 mg/80 80 mg/ first first course) patients patients (previous previous line). arm arm (6 6 p=positology positology and/achieved. achieved.",
      "start_page": 228,
      "end_page": 230
    },
    {
      "heading": "and and registration",
      "text": "cancer cancer (cancer cancer treatment).",
      "start_page": 230,
      "end_page": 230
    },
    {
      "heading": "1 1 Pleuracarcinos",
      "text": "metastasis metastasis (pleuracarcinosis) here here (see table).",
      "start_page": 230,
      "end_page": 230
    },
    {
      "heading": "fibrous fibrous tumour",
      "text": "death death (e.g., the the body). size size > relapse relapse (vg see above). this this follow- late. late.",
      "start_page": 230,
      "end_page": 231
    },
    {
      "heading": "14 14 Tables",
      "text": "Immunohistochemical Immunohistochemical (MM) from pleuracarcinoma (BAP1 BAP1 ± MTAP ± Desmin - EMA + [membraneous] Markö Calretinin + CK5 + Podoplanin (D2- + WT1 + Ma Claudin-4 - CEA - (monoclonal) EpCAM (e.g. -clone MOC-31) TAG72 (B72.3) - CK7 + CKAE1/3 + Vimentin ± + = 80 80 % positive. positive. – = Max 20 % positive positive (some some stains/diagnosures). malignant malignant okarcinomas) differentiate differentiate benign/for for mesateliomom/respectively. respectively.",
      "start_page": 232,
      "end_page": 233
    },
    {
      "heading": "Recommendations",
      "text": "• Stadium 1-2 (enl Masaoka-Koga) 2. 2. • Stadium 3 (enil Masaoca-Kogoa) offered. offered. • 4A 4A (enli Masaoke-Kogas) treatment. treatment. • for for 10–15 years.",
      "start_page": 234,
      "end_page": 234
    },
    {
      "heading": "1 1 Etiology",
      "text": "gravis gravis MG) affecting approximately 35% about about 15% tymoma tymoma [399]. about about 5% aplasia, aplasia, hypo- carcinoma carcinoma [400]. thymomomas. thymomomas.",
      "start_page": 234,
      "end_page": 234
    },
    {
      "heading": "2 2 Epidemiology",
      "text": "0. 0.13/0. 0.33/Netherlands Netherlands [399, 401]. about about 35% mediastinum. mediastinum.",
      "start_page": 234,
      "end_page": 234
    },
    {
      "heading": "3 3 Symptoms",
      "text": "local local symptoms: investigation. investigation.",
      "start_page": 235,
      "end_page": 235
    },
    {
      "heading": "4 4 Histopathology",
      "text": "for for Pathology'and and margins/of of thymoma/classification classification (in in 2021) M-codes M-codes (classification classification [402]. also also previous/risk risk [403].",
      "start_page": 235,
      "end_page": 235
    },
    {
      "heading": "thymus thymus tumours",
      "text": "Tymoma UNS (and and sclerosis) A A (type type A) ning. ning. r- type type (Beres of subtype) carcinoid carcinoid (and unspecified) M82403",
      "start_page": 235,
      "end_page": 236
    },
    {
      "heading": "Statutory Statutory classification",
      "text": "used used [404].",
      "start_page": 236,
      "end_page": 236
    },
    {
      "heading": "by by Masaoka-Koga",
      "text": "TNM TNM (Lung Lung Cancer) surgery surgery (ThoR) decisions. decisions.",
      "start_page": 236,
      "end_page": 237
    },
    {
      "heading": "6 6 Investigation",
      "text": "tomography tomography (DT) 4A 4A (pleural dispersion) and 4B (extratoracal dispersion) imaging imaging (MR) echocardiography, echocardiography, pre- thymotoms thymotoms [406]. patient. patient.",
      "start_page": 238,
      "end_page": 238
    },
    {
      "heading": "Basic Basic principles",
      "text": "ingrowth ingrowth (etc. etc.) resectable resectable [411].",
      "start_page": 238,
      "end_page": 239
    },
    {
      "heading": "2 2 Stemotomy",
      "text": "major major and/infection infection (1-2%), scar. scar. nion",
      "start_page": 239,
      "end_page": 240
    },
    {
      "heading": "3 3 WATER/RATS",
      "text": "VATS VATS (Thoracic Thoracic Surgery) disease disease (and and 2). RATS RATS (Thornacic Thornacic Surfery) of of VATS/relief relief [412).",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "Radiotherapy Radiotherapy Tymoma",
      "text": "radiotherapy radiotherapy (PORT) PORT PORT [382] today today [414]. dose dose (> 50 Gy) protocol protocol (PROTHYM) radiotherapy radiotherapy [studies. studies.",
      "start_page": 240,
      "end_page": 241
    },
    {
      "heading": "Radical resection:",
      "text": "class class B2–radioter radioter needs",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "Non-radical resection:",
      "text": "necessary. necessary.",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "and and fractionation:",
      "text": "resection resection (radiation radiation (R2)/inope tumor: 1. 1.5–volumes. volumes.",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "thymus thymus carcinoma",
      "text": "carcinoma carcinoma (WHO class C) Gy Gy [418].",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "4 4 Cytostatics",
      "text": "higher higher (70-80%) than in non-antracyclin-based (30-50%) [419]. time. time. R1): 1.8–2 erable rginal; to to 60– anthracycle anthracycle [41942]. etoposides etoposides [423], paclitaxel paclitaxel [424], gemcitabine gemcitabine [422] literature. literature.",
      "start_page": 242,
      "end_page": 243
    },
    {
      "heading": "medical medical treatment",
      "text": "expression expression [426, 427]. at at _MEDTERM7_[429]. in in __MM_30].",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "Treatment Treatment outcomes",
      "text": "in in thymoma/2 2 %, 100 100 %, 80-90 80-90 % 50 50 % [433]. 25 25 % [434). adium adium 1/2-thymomas after R0resection: adium adium 3/of of year: day. day...",
      "start_page": 243,
      "end_page": 244
    },
    {
      "heading": "of of follow-up",
      "text": "several several parts: • for for rehabilitation; • the the patient'first first check; for for recovery; • patient patient ́instruments. instruments. S: upp upp döstök) dsråd dsråd n: rall rall den: directed directed treatment",
      "start_page": 245,
      "end_page": 247
    },
    {
      "heading": "evidence evidence situation",
      "text": "guidelines guidelines [62, 435], lung lung cancer; studied studied [436]. treatment treatment [437]. treatment. treatment.",
      "start_page": 247,
      "end_page": 247
    },
    {
      "heading": "and and SBRT",
      "text": "the the patient'DT DT (upper upper abdomen) IPÖ. IPÖ.",
      "start_page": 247,
      "end_page": 248
    },
    {
      "heading": "Stadium Stadium IB-IIIC",
      "text": "the the patient'DT DT (upper upper abdomen) Regime Regime Library:",
      "start_page": 248,
      "end_page": 249
    },
    {
      "heading": "Targeted Targeted treatment",
      "text": "DT DT (upper upper abdomen) RNA RNA (called",
      "start_page": 249,
      "end_page": 249
    },
    {
      "heading": "2 2 Immunotherapy",
      "text": "DT DT (upper upper abdomen) adverse adverse reactions",
      "start_page": 249,
      "end_page": 249
    },
    {
      "heading": "Cytostatic Cytostatic therapy",
      "text": "DT DT (upper upper abdomen) recommended. recommended.",
      "start_page": 249,
      "end_page": 250
    },
    {
      "heading": "palliative palliative therapy",
      "text": "the the first- individual individual patient'DT DT (upper upper abdominal) months. months.",
      "start_page": 250,
      "end_page": 250
    },
    {
      "heading": "20.5 Liability",
      "text": "the the patient'patient patient ́this. this.",
      "start_page": 250,
      "end_page": 250
    },
    {
      "heading": "of of follow-up",
      "text": "treatment treatment at: • symptoms symptoms (of of breath) • explanation explanation • bloody cough • long-term pneumonia • hoarseness • loss loss • rehabilitation rehabilitation needs/Antit Antit (Antit Antit (‘populations populations (< care care services",
      "start_page": 251,
      "end_page": 253
    },
    {
      "heading": "Recommendations",
      "text": "• register register (NLCR). • overview overview (IPÖ) the the patient'time. time. • available available at:",
      "start_page": 254,
      "end_page": 254
    },
    {
      "heading": "Cancer Cancer Register",
      "text": "the the country'and and Welfare'register register (HSLF-FS 2016:HSL-FS HSL-FS 2023:36) providers providers (care care providers) Centre Centre (RCC) further further information: cancer centre.se/coloperation/varaignation/knowledge/cancer register.",
      "start_page": 254,
      "end_page": 254
    },
    {
      "heading": "cancer cancer register",
      "text": "Social Social Agency'SOSFS SOSFS 1984: the the pathologist/distribution distribution (TNM status). Registry Registry (NLCR).",
      "start_page": 255,
      "end_page": 255
    },
    {
      "heading": "Data Data feedback",
      "text": "own own issues: statistics.incanet.se/lunga.",
      "start_page": 255,
      "end_page": 255
    },
    {
      "heading": "the the register",
      "text": "these. these.",
      "start_page": 256,
      "end_page": 256
    },
    {
      "heading": "processes processes (SVF)",
      "text": "processes processes (SVF) SVf. SVf.",
      "start_page": 256,
      "end_page": 256
    },
    {
      "heading": "the the register",
      "text": "The The register'modules. modules.",
      "start_page": 256,
      "end_page": 256
    },
    {
      "heading": "Patient-reported Patient-reported measurements",
      "text": "meeting. meeting.",
      "start_page": 256,
      "end_page": 256
    },
    {
      "heading": "overview overview (IPÖ)",
      "text": "overview overview (IPÖ) E E • mo mu • imm reg • straw a • slu slu • modules modules for: body. body.",
      "start_page": 256,
      "end_page": 258
    },
    {
      "heading": "CHAPTER 23",
      "text": "and and island",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "levels. levels.",
      "text": "3. 3. DT/processes processes (SVF), sources. sources.",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "a a pr",
      "text": "cancer cancer Process/through through DT/conference conference (MDK) MedTERM3__ MedTERM3__ , from from Ledication",
      "start_page": 258,
      "end_page": 259
    },
    {
      "heading": "CHAPTER 24",
      "text": "Health Programme GUARANTEE",
      "start_page": 260,
      "end_page": 260
    },
    {
      "heading": "Group Group said:",
      "text": "the the patient'participated. participated.",
      "start_page": 260,
      "end_page": 260
    },
    {
      "heading": "group group m",
      "text": "cancer. cancer.",
      "start_page": 260,
      "end_page": 261
    },
    {
      "heading": "24.3 Author",
      "text": "America America (Northern Northern Ireland), Hospital, Hospital, rats: kology kology , Göt Onko et) Örebro Örebro , Dr. Dr., University University Hospital; for for Cancer",
      "start_page": 261,
      "end_page": 264
    },
    {
      "heading": "Planning Planning Group",
      "text": "group group (January 2024) below. below.",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "Name Speciality Hospital",
      "text": "Institute Institute (NIH) Rev. Rev. 2011(2):Rev. Rev.",
      "start_page": 265,
      "end_page": 293
    },
    {
      "heading": "Patient Information",
      "text": "relatives. relatives. • cancer cancer association'lung lung cancer! stigmatisation stigmatisation – lung lung cancer; you you receive! including including patients' costs costs 100:- or or 150:- 100 100 :- den den – rum rum – cancervården. cancervården.",
      "start_page": 307,
      "end_page": 310
    },
    {
      "heading": "heading heading none",
      "text": "Row 1:\nDate",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading none (column 1)",
      "text": "Row 1:\n2015",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading none (column 1)",
      "text": "Row 1:\n2018",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading none (column 1)",
      "text": "Row 1:\n2020",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading none (column 2)",
      "text": "Row 1:\n5-03-10",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading none (column 2)",
      "text": "Row 1:\n8-in in collaboration",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading none (column 2)",
      "text": "Row 1:\n0-06-02",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading none (column 3)",
      "text": "Row 1:\n. . . .",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading none",
      "text": "Row 1:\n2022-in in collaboration",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading and and prognosis",
      "text": "in in 2018–8 8 % were women. • 10 10 – women. women.• years. years. • combined. combined. • about about 28% (men 24%, women 31%). • Row",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "heading heading over over time",
      "text": "",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading over over time",
      "text": "",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading over over time",
      "text": "",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading Tobacco Tobacco smoking",
      "text": "Row 1:\nSummary • least least 80% disease. disease. • about about 10% Sweden. Sweden. • smokers. smokers. • cancer. cancer. • lung lung cancer; lung lung cancer:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading Tobacco Tobacco smoking (from Previous page)",
      "text": "",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading Recommendations",
      "text": "Row 1:\nRecommendations • mortality. mortality. • treatment. treatment. • The individual patient'contacts. contacts. • Row",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "heading heading Recommendations (column 1)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "heading heading 5.1 Introduction",
      "text": "Row 1:\nRecommendations • studies studies (NLST and NELSON) DT. DT. • population population (Swedish Swedish one) known. known. • investigated. investigated. • screening. screening.",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Heading Heading genes, genes,",
      "text": "patients. patients. • considered. considered. • profile. profile. • changes changes < up. up. • a a follow- after after 6– individual. individual. • changes changes > investigation. investigation. • changes changes (semisola, ground glass) < after after non-follow-up. • changes changes ≥ months months (sememisol) respectively. respectively. • changes changes > months. months.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "Heading Heading Nodular Nodular Changes",
      "text": "Row 1:\nRow",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "Heading Heading Nodular Nodular Changes (from Previous Page)",
      "text": "Row 1:\nType.Storlek-Follow-upRow 2:\nGroundglass,< Row",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "Heading Heading Nodular Nodular Changes (Column Column 2)",
      "text": "Row 1:\nRowRow 4:\n< RowRow 5:\n≥ months. months., component component < Road Road 6: < 6 cm",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "Heading Heading Nodular Nodular Changes (from Previous Page)",
      "text": "Row 1:\nProbability of malignancy",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "heading heading Summary",
      "text": "disease. disease. • smokers. smokers. • syndrome. syndrome. • status. status.",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "heading heading • classification, classification, by",
      "text": "svow. svow.se/FP-L1. FP-L1. • recommended. recommended.",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "Heading Heading Tumour Tumour Classification (from Previous Page)",
      "text": "a a fallowoneoveroverover?over over there: byk. byk.(CYTOLOGAT)Row 2:\nHistological type/subtypeunhistlogic type/subtypeRow 3:\nAdenokarcinoM81403POAdenocarcinotomRow 4:\nMinimal invading, non-mucinöM8141403(No equivalent)Row 5:\nRowRow 6:\nLepidicpical",
      "start_page": 63,
      "end_page": 63
    },
    {
      "heading": "Heading Heading Tumour Tumour Classification (from Previous Page)",
      "text": "European European Union? total. total.",
      "start_page": 64,
      "end_page": 64
    },
    {
      "heading": "heading heading Recommendations",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\n Row 23:\n Row 24:\n Row 25:\n Row 26:\n Row 27:\n Row 28:\n Row 29:",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "heading heading Recommendations (from previous page)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:",
      "start_page": 73,
      "end_page": 73
    },
    {
      "heading": "Heading Heading be be informed",
      "text": "Row 1:\nRowRow 2:\nRoad Road 3: RowRow 4:\nRowRow 5:\nRecurrenspares",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "Heading Heading to Patient",
      "text": "Row 1:\nNamesRow 4:\nRow",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "Heading Heading to Patient (from Previous Page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nBlock C",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "Heading Heading to Patient (from Previous Page)",
      "text": "Row 1:\nRowRow 2:\nD D and/performed performed (before before D/E)Row 3:\nno no diagnosis",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "Heading Heading to Patient (Column Column 4)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nRowRow 4:\nFor diagnosis: - Bronchooscopy/EBUS and/or - mediatinal mediatinal stagnation: - Primarily: Second Second hand: mediastinoscopyRow 5:\nRowRow 6:\nRowRow 7:\nRowRow 8:\nMDK",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "Heading Heading to Patient (Column Column 4)",
      "text": "Row 1:\nActionRow 2:\nD D and/performed performed (before before D/E)Row 3:\nRowRow 4:\nActionRow 5:\nRowRow 6:\nBlock G performed",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "Heading Heading 9.2 Names",
      "text": "Row 1:\nno no diagnosis",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "heading heading Blood Blood tests",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nstrenuous strenuous activities; Raw Raw 4: any any work;",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "Heading Heading Blood Blood tests (column 1)",
      "text": "Row 1:\nGrad",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "heading heading Blood Blood samples (column 2)",
      "text": "Row 1:\n. . . .",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "heading heading Blood Blood samples (column 2)",
      "text": "Row 1:\n;",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "Heading Heading 9.6 Bronchoscopy",
      "text": "Row 1:\nimportant important functions: • histological histological and/sampling sampling • tumour tumour (and and trakea) T4. T4. • division. division.",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "Heading Heading Mediastinal Mediastinal Stadium",
      "text": "Row 1:\nfollowing following exist: • position position • nodes nodes – cN1 – glands glands – tumor > location location (FDG FDG uptake) needed needed at: • tumour tumour ≤ Row",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "Heading Heading Pleural Pleural Diagnosis",
      "text": "Row 1:\nRow",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "heading heading  Summary recommendations",
      "text": "population. population. • obesity obesity (BMI > 30), co-morbidity. co-morbidity. • non-treatment. non-treatment. • treatment. treatment. • recommended. recommended. • Row",
      "start_page": 90,
      "end_page": 90
    },
    {
      "heading": "heading heading Stadium Stadium classification",
      "text": "Row 1:\nor or bilobectomy: 1 ppoFEV = x x (1 - y / Z) Row",
      "start_page": 94,
      "end_page": 94
    },
    {
      "heading": "heading heading Stadium Stadium classification",
      "text": "Row 1:\nin in pulmectomy: 1 ppoFEV = x x (resected resected lunga)",
      "start_page": 94,
      "end_page": 94
    },
    {
      "heading": "heading heading Stadium Stadium classification (from Previous page)",
      "text": "pedestator pedestator (non-dating non-dating and/ cells cells in: .ow 3:",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "heading heading Stadium Stadium classification (from Previous page)",
      "text": "Row 1:\nN – regional lymph nodes",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "heading heading Stadium Stadium classification (column column 1)",
      "text": "Row 1:\nTXTX",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "heading heading Stadium Stadium classification (column column 1)",
      "text": "Row 1:\nTis",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "heading heading Stadium Stadium classification (column column 1)",
      "text": "Row 1:\nT2T2",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "heading heading Stadium Stadium classification (column column 1)",
      "text": "Row 1:\nT4T4",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "heading heading Stadium Stadium classification (column column 1)",
      "text": "Row 1:\nNX",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "heading heading Stadium Stadium classification (column column 1)",
      "text": "Row 1:\nN1N1",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "heading heading Stadium Stadium classification (column column 1)",
      "text": "Row 1:\nN3N3",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "heading heading Stadium Stadium classification (column column 2)",
      "text": "a a demities: RowRow 2:\nradiological radiological methods",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "heading heading Stadium Stadium classification (column column 2)",
      "text": "",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "heading heading PERIFER PLANT",
      "text": "Row 1:\nM – remote metastases",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "heading heading PERIFER PLANT",
      "text": "",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "Heading Heading PERIFER PLANT (column 1)",
      "text": "Row 1:\nseveral metastases. (pulmonary pulmonary metastasis/Row",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "Heading Heading PERIFER PLANT (column 1)",
      "text": "Row 1:\nT-CLOSSIFICING",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "heading heading PERIFER PLANT (column 2)",
      "text": "Row 1:\n. . . .",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "heading heading PERIFER PLANT (column 2)",
      "text": "Row 1:\nstasser i",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "heading heading PERIFER PLANT (column 2)",
      "text": "",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "heading heading PERIFER PLANT (from Previous page)",
      "text": "Row 1:\nN-CLOSSIFICING",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "heading heading PERIFER PLANT (from Previous page)",
      "text": "Row 1:\nM-CLOSSIFICING",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "heading heading PERIFER PLANT (from Previous page)",
      "text": "Row 1:\nT/M",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 1)",
      "text": "Row 1:\n\"N-KLAS\"",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 1)",
      "text": "Row 1:\nM-KLAS",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 3)",
      "text": "Row 1:\nING and N0",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 3)",
      "text": "Row 1:\nING and M0",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 4)",
      "text": "",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 4)",
      "text": "",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 4)",
      "text": "Row 1:\nN0N1Row 2:\nIA1e",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 5)",
      "text": "",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 5)",
      "text": "",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 5)",
      "text": "Row 1:\nN3Row 2:\nIIIBRow 3:\nIIIBRow 4:\nIIIB row 5: IIIB row 6: IIIBRow 7:\nIIICRow 8:\nIIICRow 9:\nIVARow 10:\nIVARow 11:\nIVB",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "heading heading PERIFER PLANT (from Previous page)",
      "text": "Row 1:\nOther stages",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "heading heading PERIFER PLANT (from Previous page)",
      "text": "Row 1:\nfor for validation",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 1)",
      "text": "Row 1:\npN",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 9)",
      "text": "Row 1:\non",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 9)",
      "text": "Row 1:\non without pN1",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "heading heading PERIFER PLANT (column column 9)",
      "text": "Row 1:\nOsition",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "heading heading cell cell disorders",
      "text": "\"palliation. palliation. • metastasas. metastasas. • surgery. surgery. • metasastastastasis. metasastastastasis. • palliations. palliations. • surgery surgery (VAT) day day – with with long-long-term – a a body:",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "heading heading 2 2 Esophagit",
      "text": "Row 1:\nGrade",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "heading heading 2 2 Esophagit",
      "text": "Row 1:\n* 5-1 5-1 mg/kg/day (Grade 2) and 1-2 mg/Kg/RowRow 2:\nRowRow 3:\ndose dose ≥ weeks. weeks.",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "heading heading 2 2 Esophagit (column 1)",
      "text": "Row 1:\nGrade",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "Heading Heading  3 3 Cardiotoxicity",
      "text": "Row 1:\nMedulla",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "Heading Heading  3 3 Cardiotoxicity (column 1)",
      "text": "Row 1:\ncm3 cm3 < 03 03 cm3< RowRow 2:\nPRV medulla",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "Heading Heading  3 3 Cardiotoxicity (column 2)",
      "text": "",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "heading heading Recommendation",
      "text": "Row 1:\nRecommendation • given. given. • Hypofractional radiotherapy (SBRT) 3. 3. • Row",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "heading heading planning planning basis",
      "text": "",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "Heading Heading Radiation Radiation dose",
      "text": "Row 1:\nstage stage I-III: • afterwards. afterwards. • Gy. Gy. • CR. CR.",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "heading heading toracal toracal radiotherapy",
      "text": "Row 1:\nto to chemotherapy: • months. months. • remission. remission.",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "Heading Heading  Primary Primary Tumour",
      "text": "Row 3:\nRow 4:\n Row 6:\n1–techniques. techniques. • 5. 5. • R R = 1. 1. • grafting. grafting.",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Recommendation",
      "text": "with with _$initiated. initiated. • Patients with _/_MEDDEMM8 = expression expression (≥ 50% in tumour cells), at at _MEDTERBM0_in__",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Recommendation",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\n Row 23:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading 1 1 EGFR",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\n Row 11:",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Recommendation",
      "text": "recommended recommended (or or __ITTERM3__). for for __INTERM2_+expression expression ≥ 1% high high PD- L1 expression; in in ≥ 50 % pos tumour cells; years. years.",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "heading heading Recommendation (column 1)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\n Row 23:\n Row 24:\n Row 25:\n Row 26:",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "heading heading 1 1 General",
      "text": "disease disease (stage stage I-III), platinum platinum + radiotherapy. radiotherapy. • radiation radiation (PCI). • disease disease (stage stage IV) with with platinum+ __ITTERM1___. __ITTERM1___. • platinumum platinumum + option. option. • considered. considered. • be be considered; • considered. considered.",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "heading heading Summary",
      "text": "Row 1:\nSummary • dies dies [316]. • Row",
      "start_page": 179,
      "end_page": 179
    },
    {
      "heading": "heading heading  Contact Contact nurse",
      "text": "Row 1:\nRecommendation • nurse. nurse. • measures. measures. • continuously. continuously. • needed. needed. • smoking. smoking. • structured. structured.",
      "start_page": 193,
      "end_page": 193
    },
    {
      "heading": "heading heading Contact Contact nurse (column 1)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:",
      "start_page": 193,
      "end_page": 193
    },
    {
      "heading": "heading heading Recommendation",
      "text": "Row 1:\nRecommendation • competence. competence. • the the disease'condition. condition. • the the patient'and and patient' preferences. preferences.",
      "start_page": 196,
      "end_page": 196
    },
    {
      "heading": "heading heading Recommendations",
      "text": "Row 1:\nRecommendations • stage. stage. • the the patient'act. act. • plan. plan.",
      "start_page": 197,
      "end_page": 197
    },
    {
      "heading": "heading heading Recommendations (column 1)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:",
      "start_page": 197,
      "end_page": 197
    },
    {
      "heading": "heading heading 2 2 Fertility",
      "text": "Row 1:\nRecommendations • care. care. • model. model. • patient. patient. • Row",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "heading heading Recommendation treatment",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "Heading Heading 2 2 Existence",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:",
      "start_page": 213,
      "end_page": 213
    },
    {
      "heading": "heading heading 2 2 Epidemiology",
      "text": "renal renal failure? Row8: up-to-date Recommendations • year. year. • metastasis. metastasis. • mesthelioma. mesthelioma. • appropriate. appropriate. • line. line. • Sweden. Sweden.",
      "start_page": 221,
      "end_page": 221
    },
    {
      "heading": "heading heading 14 14 Tables",
      "text": "Row-increased.",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "heading heading 14 14 Tables",
      "text": "Row 1:\n+ = 80 80 % RowRow 2:\n– = Maximum 20 % positive positive (RowRow 3:\nfor some stains/diagnoses).",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "heading heading 14 14 Tables (column 1)",
      "text": "Row 1:\nBAP1Row 2:\nMTAPRow 3:\nDesminRow 4:\nEMA",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "heading heading 14 14 Tables (column 1)",
      "text": "Row 1:\nCalretininRow 2:\nCK5Row 3:\nPodoplanin (D2-40)Row 4:\nWT1",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "heading heading 14 14 Tables (column 1)",
      "text": "Row 1:\nClaudin-4Row 2:\nCEA (monoclonal)Row 3:\nEpCAM (clone clone MOC-31)Row 4:\nTAG72 (B72.3)",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "heading heading 14 14 Tables (column 1)",
      "text": "Row 1:\nCK7Row 2:\nCKAE1/3Row 3:\nVimentin",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "heading heading 14 14 Tables (column 1)",
      "text": "Row 1:\n+ = 80 80 % RowRow 2:\n– = max 20 % positive positive (RowRow 3:\nfor some stains/diagnoses).",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "heading heading 14 14 Tables (column 2)",
      "text": "Row 1:\n+Row 2:\n Row 3:\n-Row 4:\n±",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "heading heading 14 14 Tables (column 2)",
      "text": "Row 1:\n±Row 2:\n-Row 3:\n±Row 4:\n±",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "heading heading 14 14 Tables (column 2)",
      "text": "Row 1:\n-Row 2:\n-Row 3:\n-Row 4:\n-",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "heading heading 14 14 Tables (column 2)",
      "text": "Row 1:\n±Row 2:\n+Row 3:\n±",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "heading heading 14 14 Tables (column 3)",
      "text": "Row 1:\n+Row 2:\n Row 3:\n-Row 4:\n+ [diffus]",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "heading heading 14 14 Tables (column 3)",
      "text": "Row 1:\n+Row 2:\n+Row 3:\n+Row 4:\n±",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "heading heading 14 14 Tables (column 3)",
      "text": "Row 1:\n+Row 2:\n+Row 3:\n±",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "Heading Heading 2 2 Epidemiology",
      "text": "Row 1:\nRecommendations • Stadium 1-2 (enl Masaoka-Koga) 2. 2. • Stadium 3 (enil Masaoca-Kogoa) offered. offered. • 4A 4A (enli Masauka-Kogas) treatment. treatment. • Row",
      "start_page": 234,
      "end_page": 234
    },
    {
      "heading": "Heading Heading Thymus Thymus Tumours",
      "text": "Row 1:\nTymoma UNS (and and sclerosis)",
      "start_page": 235,
      "end_page": 235
    },
    {
      "heading": "Heading Heading Thymus Thymus Tumours (column 1)",
      "text": "Row 1:\nTymoma UNS (and and sclerosis)Row 2:\nTymom A (type type A)Row 3:\nRowRow 4:\nRowRow 5:\nRowRow 6:\nRowRow 7:\nRowRow 8:\nRowRow 9:\nAdenokarcinomaRow 10:\nRowRow 11:\nNUT carcinoma",
      "start_page": 235,
      "end_page": 235
    },
    {
      "heading": "Heading Heading to to Masaoka-Koga",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nRowRow 4:\nRowRow 5:\nTypical Carcinoid (and unspecified)",
      "start_page": 236,
      "end_page": 236
    },
    {
      "heading": "Heading Heading to to Masaoka-Koga",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\n2B",
      "start_page": 236,
      "end_page": 236
    },
    {
      "heading": "heading heading by by Masaoka-Koga (from Previous page)",
      "text": "Row 1:\nT1aIncreased/RowRow 2:\nT1b",
      "start_page": 237,
      "end_page": 237
    },
    {
      "heading": "heading heading by by Masaoka-Koga (from Previous page)",
      "text": "Row 1:\na. a.",
      "start_page": 237,
      "end_page": 237
    },
    {
      "heading": "heading heading by by Masaoka-Koga (column column 3)",
      "text": "Row 1:\nT",
      "start_page": 237,
      "end_page": 237
    },
    {
      "heading": "heading heading 4 4 Cytostatics",
      "text": "Row 3:\nClass Class B2–Non-radical Non-radical resection: and and fractionation: resection resection (R1): resections resections (R2)/inoperable tumor: 1. 1.5–Row",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "heading heading 4 4 Cytostatics (column 1)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "Heading Heading Treatment Treatment Results (from Previous Page)",
      "text": "Row 1:\nStadium Stadium 1/R0 R0 resection: Stadium Stadium 3/after after R1/R2 resection : Row",
      "start_page": 244,
      "end_page": 244
    },
    {
      "heading": "Heading Heading Treatment Treatment Results (Column Column 1)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:",
      "start_page": 244,
      "end_page": 244
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (from previous page)",
      "text": "Row 1:\nNeed-to-use rehabilitation measures",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (from previous page)",
      "text": "Row 1:\nRowRow 2:\nactivity",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 1)",
      "text": "Row 1:\nNeds",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 1)",
      "text": "Row 1:\nFatigue",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 2)",
      "text": "Row 1:\nRow",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 2)",
      "text": "Row 1:\nHot",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 3)",
      "text": "",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 3)",
      "text": "",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 4)",
      "text": "Row 1:",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 4)",
      "text": "Row 1:\nYsianRow 2:",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 5)",
      "text": "Row 1:\nKonta",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 5)",
      "text": "Row 1:\nKonta Arbet Fysio",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 6)",
      "text": "Row 1:\nact",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 6)",
      "text": "Row 1:\nactRow 2:\ntsteraRow 3:\notera",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 7)",
      "text": "Row 1:\nJuksk",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 7)",
      "text": "Row 1:\nJukskRow 2:\napeuRow 3:\napeut",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 8)",
      "text": "Row 1:\nQueues",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 8)",
      "text": "Row 1:\nQueuesRow 2:\noutRow 3:\nt",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 9)",
      "text": "Row 1:\nrska",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 9)",
      "text": "Row 1:\nrskaRow 2:",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "heading heading Follow-up Follow-up objectives (column column 10)",
      "text": "Row. Row.",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "Heading Heading of of Follow-up (from Previous Page)",
      "text": "hospitals. hospitals.",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 1)",
      "text": "Row 1:\nBasa",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 1)",
      "text": "Row 1:\nEBU",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 1)",
      "text": "Row 1:\nMulti",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 1)",
      "text": "Row 1:\nConveyance",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 1)",
      "text": "Row 1:\nProto-Proto",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 2)",
      "text": "Row 1:\nRowRow 2:\nsplashRow 3:\nkoskRow 4:\nactionRow 5:\ntions",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 2)",
      "text": "Row 1:\nUS/EU",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 2)",
      "text": "Row 1:\nidisc",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 2)",
      "text": "Row 1:\nventi",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 2)",
      "text": "Row 1:\nonbe",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 3)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\ncopi, DT/UL-Row 4:\nRowRow 5:\ninvestigation",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 3)",
      "text": "Row 1:\nUS",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 3)",
      "text": "Row 1:\nRow",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 3)",
      "text": "Row 1:\nRow",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 3)",
      "text": "Row 1:\nradiation",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 4)",
      "text": "Row 1:\nrednRow 2:\nRowRow 3:\n-ledRow 4:\nal",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 4)",
      "text": "Row 1:",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 4)",
      "text": "Row 1:\nEren's",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 4)",
      "text": "Row 1:\nehan",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 5)",
      "text": "Row 1:\nningRow 2:\nRowRow 3:\ndaRow 4:",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 5)",
      "text": "Row 1:\ns",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 5)",
      "text": "Row 1:\nndlin",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 6)",
      "text": "Row 1:\nbyRow 2:\nDT,Row 3:\n Row 4:",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 6)",
      "text": "Row 1:\nng",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 7)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 8)",
      "text": "Row 1:\nhospitals hospitals (the the country)",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 8)",
      "text": "Row 1:\nhospitals. hospitals. EBUS/hospitals. hospitals.",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 8)",
      "text": "Row 1:\nhealth health centre",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 8)",
      "text": "Row 1:\ntherapy therapy equipment",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 8)",
      "text": "Row 1:\nregional regional hospital",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 9)",
      "text": "Row 1:\nhRow 2:\ncalled",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 9)",
      "text": "Row 1:\n. andRow 2:\n, andRow 3:\nRowRow 4:\nng,Row 5:\n,Row 6:\n,andRow 7:\n-",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 9)",
      "text": "Row 1:\nd",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 9)",
      "text": "Row 1:\nus",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 9)",
      "text": "",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "Heading Heading of of Follow-up (from Previous Page)",
      "text": "Row1: regional regional hospitals",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading of of Follow-up (from Previous Page)",
      "text": "Row 1:\nRowRow 2:\nregional regional hospitals",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading of of Follow-up (from Previous Page)",
      "text": "Row 1:\nRowRow 2:\nmetastatic bronchial carcinoid",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 1)",
      "text": "Row 1:\nAntitRow 2:\nand (cyto",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 1)",
      "text": "Row 1:\nHeal meta",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 1)",
      "text": "Row 1:\nSpec",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 2)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\ngcancer",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 2)",
      "text": "RowRow 2:\nRow",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 2)",
      "text": "Row 1:\nRow",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 3)",
      "text": "Row 1:\nActionRow 2:\npi) by",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 3)",
      "text": "Row 1:\n Row 2:\ninoid",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 3)",
      "text": "Row 1:\nd",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 4)",
      "text": "Row 1:\nregional regional hospitals",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading of of Follow-up (Column Column 4)",
      "text": "Row 1:",
      "start_page": 253,
      "end_page": 253
    },
    {
      "heading": "Heading Heading Cancer Cancer Registry",
      "text": "Row 1:\nRecommendations • register register (NLCR). • overview overview (IPÖ) the the patient'time. time. • se. se.",
      "start_page": 254,
      "end_page": 254
    },
    {
      "heading": "heading heading a a pr",
      "text": "Row 1:\nNrIndicator",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "heading heading a a pr (column 1)",
      "text": "Row 1:\nNr",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "heading heading a a pr (column 2)",
      "text": "Row 1:\nRowRow 2:\nRow",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "heading heading a a pr (column 2)",
      "text": "Row 1:\nRow",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "heading heading a a pr (column 2)",
      "text": "Row 1:\nRow",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "heading heading a a pr (column 3)",
      "text": "Row 1:\nm",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "heading heading a a pr (column 3)",
      "text": "Row 1:\nin in which",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "heading heading a a pr (column 3)",
      "text": "Row 1:\nmda på",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "heading heading a a pr (from previous page)",
      "text": "dedicated. dedicated.",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "heading heading a a pr (from previous page)",
      "text": "Row 1:\nRowRow 2:\ncurative curative chemotherapy",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "heading heading a a pr (from previous page)",
      "text": "Row 1:\nuntil until 20%, 50% and 80% RowRow 2:\nundergone undergone surgery",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "heading heading a a pr (from previous page)",
      "text": "Row 1:\nuntil until 20%, 50% and 80% RowRow 2:\nRowRow 3:\nof of chemoradiotherapy",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "heading heading a a pr (from previous page)",
      "text": "Row 1:\nRowRow 2:\nlung cancer diagnosis",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "heading heading a a pr (from previous page)",
      "text": "Row 1:\nRowRow 2:\nlung cancer diagnosis",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 1)",
      "text": "Row 1:\n7.",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 1)",
      "text": "Row 1:\n9.",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 1)",
      "text": "Row 1:\n11. 11.",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 1)",
      "text": "Row 1:\n14.",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 1)",
      "text": "Row 1:\n16.16.",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 2)",
      "text": "",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 2)",
      "text": "",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 2)",
      "text": "Row 1:\n.RowRow 2:\nRowRow 3:\nRowRow 4:\nc.o(Row",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 2)",
      "text": "Row 1:\nRow",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 2)",
      "text": "Row 1:\nRow",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 3)",
      "text": "Row 1:\nd",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 3)",
      "text": "Row 1:\nmiss to",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 3)",
      "text": "Row 1:\nmiss to",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 3)",
      "text": "Row 1:\nafterRow 2:\nnose",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 3)",
      "text": "Row 1:\n. . . . AnRow 2:\n. . forRow 3:\n. .",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 3)",
      "text": "Row 1:\nAn",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 4)",
      "text": "Row 1:\nRowRow 2:\n–curative curative chemoradiotherapy",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 4)",
      "text": "Row 1:\nuntil until 20%, 50% and 80% ofRow 2:\nrespectively. respectively.",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 4)",
      "text": "Row 1:\nuntil until 20%, 50% and 80% ofRow 2:\nRowRow 3:\nof of chemoradiotherapy",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 4)",
      "text": "Row 1:\nafter after date",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "header header a a pr (column column 4)",
      "text": "Row 1:\nyears years after",
      "start_page": 259,
      "end_page": 259
    },
    {
      "heading": "heading heading 24.3 Author (from previous page)",
      "text": "Ochtakone: overk. overk. prene? (dentities): with with organ: and and more: level, Overtones: this this institution: Row",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (from previous page)",
      "text": "Row 1:\nLung Cancer-Row 2:\nscreening",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (from previous page)",
      "text": "Row 1:\nRowRow 2:\nclinical findings",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (from previous page)",
      "text": "Row 1:\nInvestigation –Row 2:\nRowRow 3:\nRowRow 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 1)",
      "text": "Row 1:\nIntroduction",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 1)",
      "text": "Row 1:\nEtiolo and Ethiolo",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 1)",
      "text": "Row 1:\nLungc scree",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 1)",
      "text": "Row 1:\nSymto clinical",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 1)",
      "text": "Row 1:\nInvestigating diagn tumor",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 2)",
      "text": "Row 1:\nning",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 2)",
      "text": "Row 1:\nogi",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 2)",
      "text": "Row 1:\nCancerRow 2:\nOne",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 2)",
      "text": "Row 1:\nRowRow 2:\nRow",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 2)",
      "text": "Row 1:\ndning –Row 2:\nRowRow 3:\nrutbredninRow 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 3)",
      "text": "Row 1:",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 3)",
      "text": "Row 1:\n Row 2:",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 3)",
      "text": "Row 1:\n Row 2:\nhRow 3:\nngRow 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 4)",
      "text": "Row 1:\nRow",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 4)",
      "text": "Row 1:\nRow",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 4)",
      "text": "Row 1:\nRow",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 4)",
      "text": "Row 1:\nRow",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 4)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 4)",
      "text": "Row 1:\nRow",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\nsRow 2:\n Row 3:",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\n Row 2:\nOnkRow 3:\nRowRow 4:\n Row 5:\nRowRow 6:\ntligheRow 7:\netssju",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\n Row 2:\n Row 3:",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\n Row 2:\n Row 3:\nRowRow 4:\n Row 5:\nRow",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\n Row 2:\n Row 3:\nallergRow 4:\n Row 5:\ncinceRow 6:\n Row 7:\n Row 8:\n Row 9:\nRow",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 6)",
      "text": "Row 1:\n Row 2:\nkologyRow 3:\n, GötRow 4:\n Row 5:\nOnkoRow 6:\net)Row 7:\nukhus",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 6)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\ndsce",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 6)",
      "text": "Row 1:\n Row 2:\n Row 3:\ngisektRow 4:\n Row 5:\nentrumRow 6:\n Row 7:\n Row 8:\n Row 9:\ndsce",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 7)",
      "text": "",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 7)",
      "text": "Row 1:\nRow 2:\ni, Clinical",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 7)",
      "text": "",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (column column 7)",
      "text": "",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "heading heading 24.3 Author (from previous page)",
      "text": "Ochakone: kation kation (kNO?) head. head.(also also means).(and and k) Overhead, Overbookings: Overland, Row: Gothenburg Gothenburg (sum only) Goth (Row 5:\nway way 8: drug drug treatment)Row 6:\nRaw Raw 9:",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (from previous page)",
      "text": "Row 1:\nRowRow 2:\nlung cancer",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 1)",
      "text": "Row 1:\nBeha lungc",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 1)",
      "text": "Row 1:\nEndoRow 2:\nabehan",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 2)",
      "text": "Row 1:\nandlinRow 2:\ndance",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 2)",
      "text": "Row 1:\nobronRow 2:\nndlin",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 3)",
      "text": "Row 1:\nRowRow 2:\ner",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 3)",
      "text": "Row 1:\nKniellRow 2:\nng",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 4)",
      "text": "Row 1:\nvRow 2:",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 4)",
      "text": "Row 1:",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Ochone: Overcrop, Overkone: Overhead, Overtones: Overkton, Overgone: Downpouring: Over- Overcurrent, Sahlgren'sRow 2:\nGothenburg Gothenburg (RowRow 3:\nRowRow 4:\n.RowRow 5:\nUppsala Uppsala (surgi surgery)Row 6:\nRowRow 12:\nUmeå Umeå (Row",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\nRow",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 6)",
      "text": "Row 1:\nshallRow 2:\ndeRow 3:\nndling)Row 4:\nRowRow 5:\n Row 6:\nRowRow 7:\nRowRow 8:\nhlgrenskaRow 9:\n,Row 10:\n Row 11:\ncountryRow 12:\nRowRow 13:\nshallRow 14:\n)Row 15:\nriverRow 16:\n Row 17:\nInskaRow 18:\n Row 19:\nukhusetRow 20:\n Row 21:\nkaRow 22:\nLing)Row 23:\nErsitysjuRow 24:\n Row 25:\nSkånesRow 26:\ng)",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 6)",
      "text": "Row 1:\nRow",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 7)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\ndemisRow 5:\n Row 6:\nniken,Row 7:\nehandRow 8:\naRow 9:\n Row 10:\n Row 11:\n Row 12:\nehanRow 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\nRyhoRow 20:\n Row 21:\n Row 22:\n Row 23:\nukhusRow 24:\n Row 25:",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 7)",
      "text": "Row 1:\nrrland",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 8)",
      "text": "",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (column column 8)",
      "text": "Row 1:\nds",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading 24.3 Author (from previous page)",
      "text": "Ochtakone with overkation: Overcaches: overkkPentakakone, overkton?. (c)the the institution: our our nations: Hospital Hospital (working therapy) Theme Theme Women'Huddinge Huddinge (physiotherapy) South South (sexuality and fertility) down,ow 4: Umeå Umeå University",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (from previous page)",
      "text": "Row 1:\nPsychosocialRow 2:\nCare",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (from previous page)",
      "text": "Row 1:\nMalignantRow 2:\npleural mesothelioma",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (from previous page)",
      "text": "Row 1:\nRowRow 2:\ncancer treatment",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 1)",
      "text": "Row 1:\nPsychiatry",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 1)",
      "text": "Row 1:\nMalig pleur",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 1)",
      "text": "Row 1:\nUppf canc",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 1)",
      "text": "Row 1:\nRegisRegis",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 1)",
      "text": "Row 1:\nPatie",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 2)",
      "text": "Row 1:\nKosocRow 2:\nEnd",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 2)",
      "text": "Row 1:\ngntRow 2:\nRame",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 2)",
      "text": "Row 1:\nfollowinRow 2:\ncerbe",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 2)",
      "text": "Row 1:\nster",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 3)",
      "text": "Row 1:\ncialtRow 2:\ntake",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 3)",
      "text": "Row 1:\n Row 2:\nesote",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 3)",
      "text": "Row 1:\nRowRow 2:\nehan",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 3)",
      "text": "Row 1:",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 4)",
      "text": "Row 1:\n Row 2:\nGand",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 4)",
      "text": "Row 1:\n Row 2:\neliom",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 4)",
      "text": "Row 1:\nafterRow 2:\nNdling",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\n Row 2:\nde",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\nRowRow 2:\nRow",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\n Row 2:\nm",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\nRow",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\n Row 2:\ng",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\nRow",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\nRowRow 2:\nhospital, Solna",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 5)",
      "text": "Row 1:\non",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 6)",
      "text": "Row 1:\nCustodial Curator,",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 6)",
      "text": "",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 6)",
      "text": "",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 6)",
      "text": "",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "heading heading 24.3 Author (column column 6)",
      "text": "Row 1:\n. . . .",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "Heading Heading Name Speciality Hospital",
      "text": ".Mary planck (sekr) Emelie Emelie Gezelius",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "Heading Heading Name Speciality Hospital (column 1)",
      "text": "Row 1:\nNamn",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "Heading Heading Name Speciality Hospital (column 2)",
      "text": "Row 1:\njukhu",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "Heading Heading Name Speciality Hospital (column 2)",
      "text": "Row 1:\nitetss",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "Heading Heading Name Speciality Hospital (column 3)",
      "text": "Row 1:\nus, Lund",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "Heading Heading Name Speciality Hospital (column 3)",
      "text": "Row 1:\nnköping",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "heading heading Name Speciality Hospital (from Previous page)",
      "text": "Row1: Oskar Grundberg",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 1)",
      "text": "Row 1:\nOskar Grundb",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 1)",
      "text": "Row 1:\nRowRow 2:\nstephanie Min",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 1)",
      "text": "Row 1:\nPer Landelius",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 1)",
      "text": "Row 1:\nJohan Botling",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 1)",
      "text": "Row 1:\nRowRow 2:\nala Muala",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 2)",
      "text": "Row 1:\nMountainRow 2:\nndus",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 2)",
      "text": "Row 1:\nYou",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 3)",
      "text": "Row 1:\nRow 2's",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 3)",
      "text": "Row 1:",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 5)",
      "text": "Row 1:\nLungm",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 5)",
      "text": "Row 1:\nLungmLungm",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 5)",
      "text": "Row 1:\nToraxk",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 5)",
      "text": "Row 1:\nClinical",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "Heading Heading Name Speciality Hospital (column column 6)",
      "text": "Row 1:\nMedic",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 7)",
      "text": "Row 1:\ncin",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 8)",
      "text": "",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 8)",
      "text": "Row 1:\nAkad",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 8)",
      "text": "",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 8)",
      "text": "Row 1:\na. a.",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 8)",
      "text": "Row 1:\nNorth",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "Heading Heading Name Speciality Hospital (column column 9)",
      "text": "Row 1:\nadem",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "Heading Heading Name Speciality Hospital (column column 9)",
      "text": "Row 1:\nrland",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 10)",
      "text": "Row 1:\nRow",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 10)",
      "text": "Row 1:\nRow",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 11)",
      "text": "Row 1:\nthe ettsjukhus, Solna",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 11)",
      "text": "Row 1:\nset, Uppsala",
      "start_page": 266,
      "end_page": 266
    },
    {
      "heading": "heading heading Name Speciality Hospital (column column 11)",
      "text": "Row 1:\nITetssjukhus, Göteborg",
      "start_page": 266,
      "end_page": 266
    }
  ]
}